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Abstract 
Skeletal muscle is a complicated and heterogeneous striated muscle tissue that serves 
critical mechanical and metabolic functions in the organism. The process of generating 
skeletal muscle, myogenesis, is elaborately coordinated by members of the protein kinase 
family, which transmit diverse signals initiated by extracellular stimuli to myogenic 
transcriptional hierarchy in muscle cells. Mitogen-activated protein kinases (MAPKs) 
including p38 MAPK, c-Jun N terminal kinase (JNK) and extracellular signal-regulated 
protein kinase (ERK) are components of serine/threonine protein kinase cascades that 
play important roles in skeletal muscle differentiation. The exploration of MAPK 
upstream kinases identified mitogen activated protein kinase kinase kinase kinase 4 
(MAP4K4), a serine/threonine protein kinase that modulates p38 MAPK, JNK and ERK 
activities in multiple cell lines. Our lab further discovered that Map4k4 regulates 
peroxisome proliferator-activated receptor γ (PPARγ) translation in cultured adipocytes 
through inactivating mammalian target of rapamycin (mTOR), which controls skeletal 
muscle differentiation and hypotrophy in kinase-dependent and -independent manners. 
These findings suggest potential involvement of Map4k4 in skeletal myogenesis.  
Therefore, for the first part of my thesis, I characterize the role of Map4k4 in skeletal 
muscle differentiation in cultured muscle cells. Here I show that Map4k4 functions as a 
myogenic suppressor mainly at the early stage of skeletal myogenesis with a moderate 
effect on myoblast fusion during late-stage muscle differentiation. In agreement, Map4k4 
expression and protein kinase activity are declined with myogenic differentiation. The 
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inhibitory effect of Map4k4 on skeletal myogenesis requires its kinase activity. 
Surprisingly, none of the identified Map4k4 downstream effectors including p38 MAPK, 
JNK and ERK is involved in the Map4k4-mediated myogenic differentiation. Instead, 
expression of myogenic regulatory factor Myf5, a positive mediator of skeletal muscle 
differentiation is transiently regulated by Map4k4 to partially control skeletal myogenesis. 
Mechanisms by which Map4k4 modulates Myf5 amount have yet to be determined.  
In the second part of my thesis, I assess the relationship between Map4k4 and IGF-
mediated signaling pathways. Although siRNA-mediated silencing of Map4k4 results in 
markedly enhanced myotube formation that is identical to the IGF-induced muscle 
hypertrophic phenotype, and Map4k4 regulates IGF/Akt signaling downstream effector 
mTOR in cultured adipocytes, Map4k4 appears not to be involved in the IGF-mediated 
ERK1/2 signaling axis and the IGF-mediated Akt signaling axis in C2C12 myoblasts. 
Furthermore, Map4k4 does not affect endogenous Akt signaling or mTOR activity during 
C2C12 myogenic differentiation.    
The results presented here not only identify Map4k4 as a novel suppressor of skeletal 
muscle differentiation, but also add to our knowledge of Map4k4 action on multiple 
signaling pathways in muscle cells during skeletal myogenesis. The effects that Map4k4 
exerts on myoblast differentiation, fusion and Myf5 expression implicate Map4k4 as a 
potential drug target for muscle mass growth, skeletal muscle regeneration and muscular 
dystrophy.       
 
vii 
 
 
 
Table of Contents 
Acknowledgments.............................................................................................................. iii 
Abstract ................................................................................................................................v 
List of Figures ......................................................................................................................x 
List of Frequently Used Abbreviations ............................................................................. xii 
Copyright Information ..................................................................................................... xiv 
CHAPTER I: Introduction ...................................................................................................1 
Myogenesis...................................................................................................................... 1 
Myogenic transcription factors .................................................................................... 2 
Paired-homeobox transcription factors .................................................................... 2 
Myogenic regulatory factors .................................................................................... 3 
Interaction of MRFs with transcriptional cofactors ................................................. 7 
Regulation of Myf5 Expression and Activity ............................................................ 10 
Transcriptional Control .......................................................................................... 10 
Post-transcriptional Control ................................................................................... 12 
Role of IGF signaling in skeletal muscle differentiation and hypertrophy ................... 13 
Regulation of skeletal muscle growth by IGF-Akt signaling .................................... 17 
IRS, PI3K and PDK1 ............................................................................................. 17 
Akt.......................................................................................................................... 17 
mTOR .................................................................................................................... 18 
GSK3β ................................................................................................................... 20 
FoxO ...................................................................................................................... 22 
viii 
 
 
 
Regulation of skeletal muscle growth by IGF-calcineurin signaling ........................ 23 
Role of MAPK signaling cascades in skeletal myogenesis........................................... 25 
JNK signaling and myogenesis .................................................................................. 26 
ERK signaling and myogenesis ................................................................................. 27 
p38 MAPK signaling and myogenesis ...................................................................... 30 
ERK5 signaling and myogenesis ............................................................................... 35 
Map4k4.......................................................................................................................... 36 
Specific Aims ................................................................................................................ 39 
CHAPTER II: Identification of Map4k4 as a novel suppressor of skeletal muscle ..........40 
Abstract ......................................................................................................................... 41 
Introduction ................................................................................................................... 42 
Materials and Methods .................................................................................................. 44 
Results ........................................................................................................................... 49 
Map4k4 expression and protein kinase activity are decreased during skeletal muscle 
differentiation. ........................................................................................................... 49 
Map4k4 silencing promotes skeletal muscle differentiation. .................................... 52 
Inhibition of myogenic differentiation by Map4k4 requires its kinase activity. ....... 57 
Map4k4 does not regulate myogenic differentiation through canonical MAPK 
signaling pathways. ................................................................................................... 59 
Map4k4 functions mainly at the early stage of myogenic differentiation. ................ 63 
Map4k4 regulates myogenic differentiation in a Myf5-dependent manner. ............. 65 
Discussion ..................................................................................................................... 70 
ix 
 
 
 
Chapter III: Map4k4 does not regulate IGF-mediated signaling pathways in C2C12 
muscle cells ........................................................................................................................75 
Abstract ......................................................................................................................... 76 
Introduction ................................................................................................................... 76 
Materials and Methods .................................................................................................. 79 
Results ........................................................................................................................... 81 
Map4k4 silencing does not alter IGF1-induced ERK1/2 phosphorylation in C2C12 
myoblasts. .................................................................................................................. 81 
Map4k4 silencing does not affect IGF1/Akt/mTOR signaling in C2C12 myoblasts. 83 
Map4k4 silencing has no impact on Akt or its downstream effector activation during 
C2C12 differentiation. ............................................................................................... 85 
Discussion ..................................................................................................................... 88 
CHAPTER IV:  Discussion ...............................................................................................92 
Role of Myf5 in skeletal muscle differentiation............................................................ 92 
Regulation of Myf5 expression by Map4k4 in C2C12 muscle cells............................. 94 
Potential role of Map4k4 in skeletal muscle development and regeneration .............. 100 
Conclusion ................................................................................................................... 102 
Appendix A ......................................................................................................................104 
References ........................................................................................................................110 
 
 
x 
 
 
 
List of Figures 
Figure 1.1 Schematic representation of skeletal myogenesis and transcriptional hierarchy 
during myogenic process .................................................................................................... 6 
Figure 1.2 Schematic displaying the main components in IGF-mediated signaling 
pathways that regulate skeletal muscle growth ................................................................. 16 
Figure 2.1 Expression and kinase catalytic activity of Map4k4 during skeletal muscle 
differentiation .................................................................................................................... 51 
Figure 2.2 Map4k4 silencing promotes myotube formation in C2C12 cells .................... 53 
Figure 2.3 Map4k4 silencing has no effect on C2C12 myoblast proliferation ................. 54 
Figure 2.4 Map4k4 silencing enhances C2C12 myogenic differentiation ........................ 56 
Figure 2.5 Map4k4 kinase activity is required for its inhibition of C2C12 myogenic 
differentiation .................................................................................................................... 58 
Figure 2.6 Map4k4 silencing does not promote skeletal muscle differentiation through 
canonical MAPK signaling pathways ............................................................................... 62 
Figure 2.7 Map4k4 functions mainly at the early stage of myogenic differentiation ....... 64 
Figure 2.8 Map4k4 silencing increases Myf5 expression ................................................. 66 
Figure 2.9 Suppression of Myf5 impairs Map4k4 silencing-enhanced myogenic 
differentiation. ................................................................................................................... 67 
xi 
 
 
 
Figure 2.10 Myf5 expression reverses the impaired myogenic differentiation caused by 
Map4k4 ............................................................................................................................. 69 
Figure 3.1 Map4k4 silencing does not alter IGF1-induced ERK1/2 phosphorylation in 
C2C12 myoblasts .............................................................................................................. 82 
Figure 3.2 Map4k4 silencing has no significant effect on the IGF/Akt/mTOR signaling 
pathway in C2C12 myoblasts ........................................................................................... 84 
Figure 3.3 Map4k4 silencing has no impact on activation of Akt or its downstream 
effectors during C2C12 differentiation ............................................................................. 87 
 
 
 
 
 
 
 
 
xii 
 
 
 
List of Frequently Used Abbreviations 
Abbreviation                        Term 
Map4k4                                         Mitogen-activated protein kinase kinase kinase kinase 4 
MRF                                              Myogenic regulatory factor  
MEF2                                            Myocyte enhancer factor 2 
MyHC                                           Myosin heavy chain  
MAPK                                           Mitogen-activated protein kinase  
JNK                                               c-Jun N terminal kinase 
ERK                                              Extracellular signal-regulated protein kinase 
IGF                                                Insulin-like growth factor  
PI3K                                              Phosphatidylinositol 3-kinase 
Akt                                                Protein kinase B 
mTOR                                           Mammalian target of rapamycin  
4EBP1                                           eIF4E-binding protein-1 
eIF4E                                            Eukaryotic initiation factor 4-E 
p70S6K1                                       p70 ribosomal S6 kinase-1 
xiii 
 
 
 
GSK3                                            Glycogen synthase kinase 3 
FoxO                                             Forkhead box protein O 
MAFbx                                         Muscle atrophy F-box 
MuRF1                                         Muscle RING finger 1 
NFAT                                           Nuclear factor of activated T cell  
RSPO3                                          R-spondin 3 
TNFα                                            Tumor necrosis factor α 
siRNA                                           Small interfering RNA 
Ad                                                 Adenovirus 
wt                                                 Wild type 
GM                                               Growth medium 
DM                                               Differentiation medium  
  
 
 
 
xiv 
 
 
 
Copyright Information 
Chapter II of this dissertation has appeared in: 
Mengxi Wang, Shinya U. Amano, Rachel J. Roth Flach, Anil Chawla, Myriam Aouadi, 
Michael P. Czech. Identification of Map4k4 as a novel suppressor of skeletal muscle 
differentiation. Molecular and Cellular Biology, 2013, 33:678-687 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
CHAPTER I: Introduction 
Myogenesis 
Skeletal muscle is a striated muscle tissue with complicated and heterogeneous features 
that serves multiple critical functions in the organism. Vertebrate skeletal muscle of the 
trunk and limbs originates from the somites, which are mesodermal structures that are 
located on either side of the neural tube in vertebrate embryos (201). In response to the 
signals from distinct environmental cues, somites differentiate and subdivide into two 
compartments, the dorsal dermomyotome and the ventral sclerotome. Myogenic 
precursors in the dermomyotome subsequently give rise to myotomes, which are 
responsible for the formation of the trunk and deep back muscles (130). Meanwhile, 
some of the cells from the lateral edge of the dermomyotome undergo epithelial-
mesenchymal transition and delaminate and migrate to the limb buds, where they give 
rise to limb musculature following sequential steps including myoblast specification, 
myocyte differentiation and fusion, and mature myofiber formation (50, 76).  
During murine skeletal muscle development, myoblasts are derived from two distinct 
progenitor populations and contribute to two phases of myogenesis (121). The first wave 
of mononucleated myocyte fusion into multinucleated myofibers occurs at approximately 
embryonic day 11 (E11) and is defined as primary or embryonic myogenesis, in which 
basic muscle patterning occurs. The secondary, or fetal myogenesis that occurs between 
E14.5 and E17.5 is characterized by fusion of fetal myocytes with each other, or their 
alignment and fusion with the scaffold-like primary myotubes to form secondary 
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myofibers (177). At the end of this phase, each myofiber is coated by basal lamina, 
underneath which some muscle progenitors termed satellite cells are located. Satellite 
cells normally remain quiescent in adult muscles, but they can be activated upon injury 
and aid in muscle regeneration. Satellite cell-mediated muscle regeneration is highly 
similar to developmental myogenesis, as evidenced by common transcription factors and 
molecular signals that modulate these scenarios (260, 299).  
Myogenic transcription factors 
Paired-homeobox transcription factors  
Myogenesis is elaborately controlled by intrinsic genetic hierarchies of myogenic 
transcription factors. During mouse muscle development, the precursor cells in the 
dermomyotome express paired-homeobox transcription factors pax3 and pax7, with 
preferential expression of pax3 in the dosalmedial and ventrolateral lips, and pax7 in the 
central region where satellite cells originate (101, 135). Of note, only pax3 is detected in 
the migrating cells that enter the limb bud. To support this observation, Splotch mice with 
a pax3 loss-of-function mutation fail to develop limb muscles, and no pax3-positive cells 
are detected in the limb, indicating a lack of progenitor migration to the site (66). 
Consistently, pax3-deleted mice lose all of their embryonic myofibers (121), further 
supporting that pax3 is required for normal skeletal muscle development. In contrast, 
pax7 is dispensable for embryonic or fetal myogenesis because pax7-/- mice do not 
display skeletal muscle formation defects (243). Instead, a complete absence of satellite 
cells is observed in the mutant mice (228, 243). However, Hutcheson et al. demonstrated 
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an essential role for pax7 in fetal myogenesis by ablating pax7-expressing cells from 
mouse embryos (121). Pax7 lineage deletion resulted in the loss of fetal (secondary) 
myofibers, consistent with the observation that pax7 is expressed in fetal myoblasts (22, 
119). Based on these studies, one may propose that pax3 is critical for initial myofiber 
formation, which then serves as a template for pax7-positive cells to form secondary 
fibers, and pax7 is required to maintain the satellite cell pool.     
Myogenic regulatory factors 
Pax3+pax7+ progenitors are mitotically active and cannot differentiate into myotubes 
(135), suggesting that molecules other than pax3 and pax7 are responsible for myogenic 
induction and precursor cell differentiation. The discovery of MyoD, a transcription 
factor that is able to convert mouse pluripotent mesenchymal C3H10T1/2 cells into 
fusion-capable myoblasts (68) sheds light on the molecular nature of muscle 
differentiation. Subsequent studies revealed three more transcription factors: Myf5, 
myogenin and MRF4, which are also able to induce myoblast traits in non-muscle cells 
(38-39, 83). Characterized by their collective expression in the skeletal muscle lineage, 
these four transcription factors are termed myogenic regulatory factors (MRFs). MRFs 
have a conserved basic helix-loop-helix (bHLH) DNA binding domain and relatively 
variable N-terminal and C-terminal domains to mediate transcriptional activation. The 
HLH domain also facilitates heterodimerization between MRFs and E-proteins that 
recognize the E-box consensus sequence CANNTG, which is present in many muscle-
specific gene promoters (250). 
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Myf5 is the first MRF expressed within the dermomyotome on the eighth day of mouse 
embryonic development, and its expression starts to decrease on E11 (43). In contrast, 
MyoD is expressed at approximately E10.5, and myogenin transcripts begin to 
accumulate immediately after MyoD activation (37). Two waves of MRF4 expression 
have been observed in mouse embryogenesis. The first wave occurs between E9 and 
E11.5 and the second one starts at E16 and persists through adulthood (210). Genetic 
studies in mice indicate redundant and differential roles of MRFs in myogenesis. Mice 
lacking Myf5 or MyoD have no major defects in muscle development. Myf5-null mice 
have normal skeletal muscle morphology and muscle-specific gene expression, while the 
appearance of myotome cells is delayed until MyoD is expressed (41). Similarly, 
myogenesis in Myf5-null mice is fully restored by a MyoD-expressing lineage (97, 105). 
MyoD deletion results in prolonged and elevated Myf5 expression, which functionally 
compensates for MyoD and leads to normal skeletal musculature (236). Interestingly, 
Myf5/MyoD double-null mice are completely absent of skeletal myoblasts or myofibers 
as well as myogenin expression (237). These observations indicate that Myf5 and MyoD 
play partially redundant roles in myogenic cell fate determination and myoblast 
commitment. Myogenin-mutant mice have severe defects in muscle fiber formation with 
reduced muscle-specific gene expression such as myosin heavy chain and MRF4. 
However, Myf5 and MyoD expression appears normal, and mononucleated myoblasts are 
observed in the limbs (110, 191), suggesting that myogenin is essential for committed 
myoblast differentiation and acts downstream of Myf5 and MyoD. Consistent with its 
biphasic expression pattern, MRF4 has a dual role in muscle development. Functional 
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MRF4 presence supports myotome differentiation in the Myf5/MyoD double-null mice 
(134), indicating a potential myogenic determination role that MRF4 plays as Myf5 and 
MyoD. MRF4-/- mice have normal skeletal muscle development and demonstrate strong 
myogenin up-regulation, which may compensate for the absence of MRF4 (304). 
However, MyoD/MRF4 double mutations result in a severe muscle deficiency that is 
similar to the myogenin-mutant mice (225). Thus, this upregulation of myogenin 
expression was insufficient to induce myogenesis, suggesting that MRF4 and MyoD have 
overlapping functions in myoblast differentiation. Taken together, these studies reveal a 
hierarchical relationship between MRFs whereby Myf5 locates at the top of the hierarchy 
and collaborates with MyoD in a redundant fashion to specify myoblasts, while 
myogenin and MRF4 act genetically downstream to induce myoblast differentiation and 
muscle-specific gene expression (Fig 1.1). 
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Figure 1.1  Schematic representation of skeletal myogenesis and transcriptional 
hierarchy during myogenic process. Myoblast commitment is marked by the onset of 
Myf5 and MyoD expression that is regulated by Pax3 and Pax7, which are master 
regulators of early lineage specification in muscle precursor cells. Myogenin expression 
further commits myoblasts to the myogenic program. Differentiating myogenin-positive 
myocytes align and fuse to form nascent myotubes. MRF4 is further required for the 
mature, multinucleated myotube formation. Myosin is a typical muscle structural protein 
that marks sarcomeric assembly in myotubes at the late stages of myogenesis. Satellite 
cell-mediated regenerative myogenesis is highly similar to developmental myogenesis 
with comparable myogenic process and transcriptional hierarchy.  
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Interaction of MRFs with transcriptional cofactors 
Numerous studies in muscle cell lines and animal models indicate that skeletal myotube 
formation and myogenic gene expression requires cooperation among MRFs and other 
molecules. During myogenesis, MRFs function as heterodimers with E proteins (E12, 
E47 and HEB), which are proteins that also belong to the bHLH transcription factor 
family and bind to E boxes in many muscle-specific gene promoters (148). In 
proliferating myoblasts, active Myf5/E protein or MyoD/E protein heterodimers are 
disrupted by the HLH protein Id (inhibitor of differentiation), which can form complexes 
with E proteins or MRFs through HLH domain interactions. Id proteins lack the basic 
DNA binding domain; thus, Id/E or Id/MRF heterodimers fail to bind E boxes in muscle 
promoters (53, 125). Id protein levels are decreased at differentiation onset (125), 
allowing for functional Myf5/E protein or MyoD/E protein heterodimer formation, and 
thus myogenic gene expression. 
Full activation of muscle-specific gene expression by MRFs requires their collaboration 
with myocyte enhancer factor 2 (MEF2) proteins (MEF2A-D), which belong to the 
MADS (MCM1, agamous, deficiens, SRF) family of transcription factors (25). MEF2 
proteins cannot activate muscle-specific genes on their own, but they potentiate the 
transcriptional activity of MRFs by interacting with the MRF/E protein complexes (181-
182). Consistently, the A/T rich sequence for MEF2 binding is often close to the E-box 
sequences within muscle genes (99). In addition to activating muscle structural genes, 
MEF2 proteins mediate myogenic bHLH gene expression in a positive feedback 
mechanism. Upstream signals activate Myf5 and MyoD, which cooperate with MEF2 
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proteins to induce myogenin expression (127, 298). Myogenin up-regulates MEF2 (63), 
which not only acts on the myogenin promoter to amplify gene expression (81), but also 
autoregulates its own promoter (276). Moreover, MRF4 expression requires synergistic 
function between MEF2 and MRFs such as myogenin (24, 192). All of these auto- and 
cross-regulatory interactions provide an elaborate transcriptional circuit to modulate 
myogenic differentiation. During mouse skeletal muscle development, Mef2c is the first 
member of the MEF2 family to be expressed followed by Mef2a and Mef2d (82). Mef2a 
or Mef2d homozygous mutant mice display no muscle developmental defects (216-217). 
However, skeletal muscle-specific Mef2c deletion resulted in disorganized myofibers, 
disrupted muscle structural gene expression and perinatal lethality, although embryonic 
and fetal myogenesis appear to be normal (216), indicating that MEF2C is required for 
the skeletal muscle postnatal maturation, but not early development. Notably, forced 
active MEF2 expression in mouse skeletal muscle did not trigger premature myogenic 
differentiation (217), suggesting that MEF2 was not sufficient for this process.  
Muscle-specific gene sequences are occupied by nucleosomes that consist of 146 DNA 
base pairs that are wrapped around a histone octamer in cellular chromatin. The 
condensed nucleosomal organization prevents access of transcription factors including 
MRFs and MEF2 proteins to the regulatory regions of these genes, resulting in 
transcriptional repression. Therefore, chromatin modification and remodeling are 
required to relax the chromatin and allow for transcription factor access.  
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One specific chromatin modification is acetylation, which loosens histone-DNA 
interactions. Several transcriptional co-activators in muscle including p300, a functional 
homolog of CREB-binding protein (CBP) and p300/CBP-associated factor (PCAF) have 
intrinsic histone acetyltransferase (HAT) activity; conversely, histone deacetylases 
(HDACs) repress transcription in skeletal muscle (174). MRFs and MEFs interact with 
HATs and HDACs. p300 stimulates muscle-specific gene expression by interacting with 
MyoD to potentiate its transcriptional activity in human and mouse muscle cell lines (220, 
239, 300). This enhanced MyoD-mediated gene transcription is not only because of 
chromatin acetylation and relaxation, but also because of direct acetylation at 
evolutionarily-conserved lysines on MyoD by p300 and PCAF (80, 215, 240). MyoD 
mutants that cannot be acetylated display impaired DNA target affinity, transcriptional 
activity and differentiation potential in vitro (215, 240). Mice with knock-in acetylation-
deficient MyoD mutations phenocopy MyoD-/- mice and display delayed myogenesis (80). 
p300 also interacts with MEF2 and acetylates it in skeletal muscle, resulting in enhanced 
DNA binding ability, transcriptional activity and myogenic differentiation (164, 239). 
Conversely, HDACs inhibit muscle-specific gene expression and myogenic 
differentiation by interacting with MyoD and MEF2 (162, 168, 221). Moreover, MEF2C 
activates HDAC9 expression, providing a negative feedback mechanism to prevent 
excessive MEF2 activation (104).  
In addition to acetylation, chromatin remodeling is modulated by factors that loosen 
histone-DNA interactions using energy from ATP hydrolysis. The SWI/SNF 
(switching/sucrose non-fementing) complex is an important chromatin-remodeling 
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enzyme, which consists of an ATPase subunit brahma-related gene 1 (BRG1) and BRG1-
associated factor BAF. Several studies have demonstrated that the SWI/SNF complex 
plays a crucial role in MyoD and myogenin-mediated muscle gene activation and 
myogenic differentiation (70, 198-199). On muscle gene regulatory elements, MyoD 
interacts with SWI/SNF subunit BAF60c, which recruits the catalytic subunit BRG1 to 
form a functional SWI/SNF complex in differentiating muscle cells, thereby facilitating 
chromatin remodeling and MyoD-targeted gene expression (90).   
Regulation of Myf5 Expression and Activity 
Transcriptional Control 
A complex interplay of developmental signals from various embryonic tissues accounts 
for Myf5 activation during skeletal muscle development. The Myf5 transcriptional 
regulatory region contains a large number of enhancer elements, which span 140 kb 
upstream of the Myf5 start site (42, 91). Sonic hedgehog (Shh), a signaling molecule that 
is secreted from the notochord and floor plate, induces Myf5 transcription through a Gli 
binding site in the epaxial enhancer in somite epaxial muscle progenitors, resulting in 
muscle cell lineage specification (30, 103). Myf5 is also a direct target of canonical Wnt 
signaling, in which activated β-catenin binds to the Tcf/Lef sequences immediately 
proximal to the Myf5 early epaxial enhancer and induces Myf5 expression 
spatiotemporally (29). Mice that are deficient for Wnt1 and Wnt3a, which are secreted 
from the dorsal neural tube and activate the Wnt/β-catenin signaling redundantly display 
decreased Myf5 expression and a lack of a medial dermomyotome compartment (122). In 
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mouse myogenic C2C12 cell lines, a Wnt/β-catenin signaling activator R-spondin2 
(RSPO2) up-regulates Myf5 expression and induces myogenic differentiation through the 
canonical Wnt pathway (107). Consistently, Myf5 mRNA levels are dramatically reduced 
in RSPO2-null mouse embryo limbs (107). In contrast to the Shh and Wnt-mediated 
Myf5 up-regulation, bone morphogenetic protein (BMP), which is expressed in the lateral 
plate mesoderm, inhibits Myf5 expression in Pax3-expressing dermomyotomal cells (218, 
230), and Noggin, a BMP antagonist that is up-regulated by Shh and Wnt (116, 172, 230) 
enhances Myf5 transcription (230).    
Pax3 acts genetically upstream of Myf5 during hypaxial myogenesis (13). Myf5 
expression is directly modulated by Pax3 through the limb bud enhancer, which is a 145 
bp regulatory element that contains a Pax3 consensus site (13). Pax3 also activates Myf5 
expression indirectly through up-regulating doublesex and mab-3 related transcription 
factor 2 (Dmrt2), which induces Myf5 expression by binding to the early epaxial Myf5 
enhancer in the dermomyotome, leading to the myogenic lineage determination (242).  
Several independent studies have suggested that other factors are involved in Myf5 
transcriptional activation. As mentioned above, muscle gene expression requires HAT-
mediated chromatin modification. Roth JF et al. demonstrated that p300 protein is 
essential for Myf5 induction and myogenesis in mouse and embryonic stem (ES) cells 
(234). In that study, Myf5 expression was severely compromised in mouse embryos 
lacking p300. p300-null ES cells also failed to induce Myf5 and MyoD expression (234). 
In the C2C12 cultured myogenic cell line, myoblast Myf5 expression is positively 
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regulated by the glucocorticoid receptor and AP-1 transcription factors, while protein 
kinase C (PKC) inhibits Myf5 transcription in these cells (10). In mononucleated muscle 
reserve cells, which are non-dividing satellite cell-like cells in myotube cultures, 
activation of calcineurin or its downstream target nuclear factor of activated T cells 
(NFAT) is necessary and sufficient to induce Myf5 transcription (95). However, the 
calcineurin- and NFAT-dependent Myf5 up-regulation is not detected in proliferating 
myoblast cultures, indicating that Myf5 is modulated by different pathways in distinct 
cell populations (95). This observation is consistent with the in vivo discovery that 
distinct signals differentially regulate Myf5 expression in various locations in the 
embryos.       
Post-transcriptional Control 
Myf5 is post-transcriptionally regulated through translation inhibition by microRNAs. 
Satellite cells remain quiescent in healthy adult skeletal muscles and express Myf5 and 
MyoD upon differentiation towards the myogenic lineage during muscle regeneration. 
The majority of quiescent satellite cells transcribe the Myf5 gene, which remains 
untranslated because of miRNA-31-dependent sequestration of the transcripts in 
messenger ribonuleoprotein (mRNP) complexes. Once satellite cells are activated, the 
mRNP granules are dissociated with reduced miRNA-31 binding to the gene, resulting in 
Myf5 protein accumulation and thereby myogenic differentiation initiation (62).     
Post-translational modifications modulate Myf5 abundance and transcriptional activity. 
Myf5 undergoes cell cycle-dependent proteolysis in proliferating myoblasts and non-
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muscle cells such as Xenopus eggs (78, 156). The mitotic stability of Myf5 protein is 
controlled by its phosphorylation status with a strong correlation detected between Myf5 
degradation and its extensive phosphorylation, while hyperphosphorylated Myf5 is stable 
(78). Multiple kinases such as cyclin-dependent kinase 1 (CDK1) and ERK as well as the 
phosphatase calcineurin are involved in the phosphorylation-dependent increase in Myf5 
stability (78). Myf5 is phosphorylated on serine49 and serine133 by protein kinase CK2 
in vitro (179). Mutants that cannot be phosphorylated fail to activate E-box-dependent 
reporter genes and act as dominant repressors of wild-type Myf5 (179), indicating that 
CK2-mediated Myf5 phosphorylation is essential for its transcriptional activity. One 
study by Winter B et al. revealed that Myf5 activity is suppressed by cAMP-dependent 
protein kinase (PKA) in the cAMP-induced inhibition of myogenic differentiation (288). 
Although PKA phosphorylates Myf5 in vitro, it does not affect Myf5 DNA binding 
ability, suggesting a potential mechanism by which phosphorylated Myf5 acts 
downstream of DNA binding to regulate transcriptional target gene activation (288).      
 
Role of IGF signaling in skeletal muscle differentiation and hypertrophy 
Insulin-like growth factor (IGF) signaling regulates many aspects of survival, growth, 
differentiation and metabolism in a wide range of cell types and mammalian tissues. The 
pathway is activated by the binding of IGF isoforms IGF1 or IGF2 to the IGF receptor 
(IGFR), which contains a tyrosine kinase domain that is activated by autophosphorylation 
upon ligand binding. Two primary signaling pathways have been proposed to be 
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associated with IGFR activation. One pathway involves the Ras-Raf-MEK-ERK module, 
which will be described in the following section. Alternatively, activated IGFR provides 
docking sites for insulin receptor substrate (IRS) proteins that recruit and activate 
phosphatidylinositol-3-kinase (PI3K) once phosphorylated by IGFR. PI3K 
phosphorylates membrane phospholipids, generating phosphatidylinositol (3,4)-
bisphosphate (PI(3,4)P2) and phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3), 
which recruits and localizes phosphoinositide-dependent kinase (PDK) and Akt to the 
inner plasma membrane surface. Co-localization of these two kinases allows PDK to 
phosphorylate Akt at multiple sites, resulting in Akt activation (150). Akt substrates 
include glycogen synthase kinase 3β (GSK3β), class O of forkhead box transcription 
factors (FoxO) and Bcl2-associated agonist of cell death (BAD), which are involved in 
protein synthesis, protein degradation and apoptosis (171). Akt also stimulates protein 
synthesis by signaling to mammalian target of rapamycin (mTOR) (147) (Fig 1.2).  
Both IGF1 and IGF2 promote myoblast proliferation and differentiation in multiple 
muscle cell lines (84, 89, 251, 268). Myoblasts begin to actively express IGF2 upon 
serum withdrawal, and autocrine IGF2 secretion is crucial for myogenic differentiation 
(89). Forced IGF1 expression in mouse skeletal muscle resulted in muscular hypertrophy 
and preserved its regenerative capacity during aging (15, 56, 88, 188). Conversely, IGF1 
or IGF1 receptor deletion caused dramatic muscle hypoplasia and severe growth 
retardation, and most of these null mice died perinatally (14, 158, 219). Similarly, 
skeletal muscle-specific IGF1R deletion or dominant negative IGF1R expression in mice 
impaired muscle development and regeneration (87, 113, 173).  
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IGF regulates mitogenesis and myogenesis through distinct signaling pathways. IGF-
induced ERK activation is mainly responsible for its mitogenic action, although the IGF-
Akt axis may be critical for proliferation as well (112, 273). The myogenic and 
hypertrophy-promoting action of IGF has been proposed to act mainly through IGF-Akt 
signaling and IGF-calcineurin signaling (Fig 1.2). In the following sections, these two 
signaling cascades will be dissected, and the components of each pathway will be 
discussed for their roles in myogenic differentiation.  
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Figure 1.2 Schematic displaying the main components in IGF-mediated signaling 
pathways that regulate skeletal muscle growth. Solid line indicates direct modification 
and dotted line indicates indirect regulation.   
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Regulation of skeletal muscle growth by IGF-Akt signaling 
IRS, PI3K and PDK1 
As mentioned above, receptor-bound IGF signals through IRS and its downstream targets 
PI3K and PDK1 to activate Akt. IRS1 disruption retards growth in mice (8), while IRS2 
deficiency leads to nearly normal growth but severe insulin resistance (289). Numerous 
studies have identified PI3K as a crucial mediator in myogenesis because IGF-induced 
myotube formation was prevented by PI3K inhibitor treatment, whereas constitutively 
active PI3K expression enhanced myogenic differentiation in the absence of IGF1 in 
muscle cell lines (126, 131, 190, 268). However, skeletal muscle-specific PI3K 
inactivation by p85 regulatory subunit deletion resulted in normal muscle size (163), as 
did the muscle-specific PDK1 knockout (185).    
Akt 
Akt is the key node in the IGF signaling cascade and mediates multiple downstream 
effectors to regulate skeletal muscle differentiation and hypertrophy. Three Akt isoforms 
have been identified, of which Akt1 and Akt2 are ubiquitously expressed in various 
tissues and Akt3 is detected in testis and brain. Evidence from an array of studies 
suggests that Akt1 and Akt2 play distinct roles during myogenesis. Akt1 levels remain 
constant during differentiation of several muscle cell lines, whereas Akt2 expression is 
up-regulated during this process (133, 235, 273). Akt1 and Akt2 are distributed 
throughout both the cytoplasm and nuclei in proliferating myoblasts. In contrast, Akt2 
translocates to myotube nuclei, whereas Akt1 is only detected in the cytoplasm (273). 
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Consistent with these observations, Akt1 appears dispensable for myogenesis but is 
required for proliferation (112, 114, 273), while Akt2 promotes myogenic differentiation 
(114, 133, 258, 273). A positive feedback regulation loop has been reported between 
Akt2 and MyoD-MEF2. Akt2 activated MyoD-MEF2 transcriptional activity and 
enhanced myogenin expression during C2C12 differentiation. Meanwhile, MyoD induced 
Akt2 transcription by binding to multiple E-box sites on the Akt2 promoter (133). Akt2 
can also phosphorylate p300 and promote the association of MyoD with p300 and PCAF 
acetyltransferases, resulting in a conformational change in the chromatin allowing access 
of MyoD to muscle-specific gene promoters (246). Moreover, prohibitin2/repressor of 
estrogen activator (PHB2/REA), a transcriptional repressor of myogenesis has been 
found to interact with Akt2, which down-regulates REA during muscle differentiation 
(114). Of note, Rotwein’s group discovered that selective elimination of Akt1 had no 
effect on proliferation but inhibited differentiation by impairing MyoD transcriptional 
activity. However, Akt2-deficient myoblasts differentiated normally and only appeared to 
have a moderate defect in maturation (235, 286). The selective control of skeletal muscle 
differentiation by Akt1 has been partially supported by the retarded growth and increased 
apoptosis phenotype in Akt1 null mice (49, 51). In contrast, Akt2 disruption in micee 
caused no growth defect but impaired glucose metabolism and insulin resistance (92). In 
adult mouse skeletal muscle, Akt activation promotes dramatic hypertrophy and prevents 
denervation-induced atrophy (23, 27, 146), indicating an additional manner by which Akt 
regulates skeletal muscle growth.        
mTOR 
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One of the best-studied downstream targets of Akt is mTOR, which is a master regulator 
of cell growth and proliferation. Akt can directly phosphorylate and activate mTOR, or 
can indirectly activate mTOR by phosphorylating and inhibiting the tuberous sclerosis 
complex (TSC) protein 1/2 complex. TSC 1/2 acts as a GTPase activating protein (GAP) 
to suppress the small G protein Ras homolog enriched in brain (Rheb) that activates 
mTOR signaling. mTOR forms two functionally and structurally distinct multiprotein 
complexes, the rapamycin-sensitive, Raptor-bound mTOR complex 1 (mTORC1) and the 
rapamycin-insensitive, Rictor-bound mTOR complex 2 (mTORC2). A major role of 
mTORC1 is to control protein synthesis through modulating two well-characterized 
substrates p70 ribosomal S6 kinase 1 (p70S6K1) and eIF4E binding protein 1 (4EBP1). 
mTORC1 activates p70S6K1, which phosphorylates the small ribosomal subunit S6 to 
initiate efficient translation of mRNAs that contain 5’-terminal oligopyrimidine tracts. 
4EBP1 phosphorylation by mTORC1 releases its inhibitory binding to eIF4E and allows 
5’-cap-dependent translation initiation. mTORC2 signals to actin organization through 
PKC and Rho family GTPases RhoA and Rac1. mTORC2 also phosphorylates and 
activates Akt (147, 280). 
An essential role of mTOR has been implicated for both skeletal muscle differentiation 
and hypertrophy (85-86, 207-208, 248). Interestingly, the myogenic function of mTOR 
during early differentiation does not require its kinase activity and involves neither of the 
downstream effectors p70S6K1 or 4EBP1 (85). Instead, mTOR regulates myogenesis by 
inducing IGF2 transcription by a kinase-independent mechanism (86). During skeletal 
myotube maturation, however, mTOR catalytic activity is crucial for the secretion of 
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unidentified factors that are required for myoblast-myotube fusion (207). IGF1-induced 
myotube hypertrophy also demands mTOR kinase activity and employs p70S6K1 as a 
downstream effector (208). A specific role of mTORC2 signaling in myogenic 
differentiation has been implied in a study where Rictor but not Raptor suppression 
reduced Akt phosphorylation and prevented C2C12 myoblast fusion (247). However, 
mouse skeletal muscles lacking Rictor are distinguishable from wild type controls with 
normal muscle size, while Raptor-deficient muscles progressively develop dystrophy (20). 
Exacerbated myopathic features were observed in skeletal muscle-specific mTOR 
depleted mice, probably because mTOR but not Raptor deficiency resulted in reduced 
dystrophin content, which is a protein complex that is essential for normal muscle 
structure and function (231). As a downstream mTOR effector, p70S6K1 depletion 
reduced muscle fiber size with unaltered myonuclei number, suggesting an atrophy 
phenotype (197).  
GSK3β 
Another effector that is involved in IGF-induced myogenic differentiation is GSK3β. 
Once inactivated by Akt phosphorylation at Ser9, GSK3β stimulates myoblast 
differentiation and fusion and increases myogenic gene expression (205, 232, 271). One 
factor that is regulated by GSK3β is NFATc3, which translocates into the nucleus and up-
regulates myogenic genes in the absence of GSK3β-mediated phosphorylation (205, 272, 
274). GSK3β inactivation by inhibitors such as LiCl also enhances NFATc3 
transcriptional activity and muscle-specific gene expression without affecting Akt 
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phosphorylation (205, 271-272), indicating that inhibiting GSK3β activity is sufficient to 
stimulate muscle differentiation independently of IGF.  
Canonical wnt/β-catenin signaling is another pathway that regulates myogenesis in a 
GSK3β-dependent manner. Under basal conditions, GSK3β and other proteins form a 
protein complex in which phosphorylated β-catenin is targeted for degradation by the 
ubiquitin-proteasome pathway. In the presence of wnt signals, the degradation complex is 
inactivated and GSK3β can no longer phosphorylate β-catenin, resulting in protein 
accumulation and its subsequent translocation into nucleus. Cytoplasmic β-catenin co-
localizes with cadherins at cell-cell contact sites and is essential for myoblast fusion and 
late stages of myogenic differentiation (124, 143, 186). Nuclear β-catenin binds to 
TCF/LEF transcription factors and induces expression of target genes such as Myf5 (107, 
261). During mouse embryogenesis, canonical wnt/β-catenin signaling is associated with 
Myf5 expression and dermomyotome formation (29, 122).   
GSK3β has been implicated in IGF-induced skeletal muscle hypertrophy (233, 262). 
Ectopic expression of a dominant negative GSK3β causes dramatic hypertrophy in 
skeletal myotubes (233), probably by preventing the inhibitory phosphorylation on 
eukaryotic initiation factor 2B (eIF2B), which promotes translation initiation and protein 
synthesis (75, 282). A recent study suggested a novel mechanism by which GSK3β 
promotes muscle growth. GSK3β phosphorylates neublin on the Z bands of myofibrils, 
thus preventing its interaction with neuronal Wiscott-Aldrich syndrome protein (N-
WASP), which is an essential factor for actin assembly. IGF-induced GSK3β inactivation 
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recruits N-WASP to the unphosphorylated neublin and promotes actin nucleation and 
actin filament elongation. Because myofiber hypertrophy is associated with enhanced 
myofibrillogenesis, it is proposed that IGF-Akt signaling regulates muscle maturation and 
hypertrophy through the GSK3β-neublin-N-WASP pathway (262).      
FoxO 
FoxO transcription factors are Akt substrates that play roles in both IGF-induced 
myoblast proliferation and differentiation. Akt phosphorylates FoxO1 at Ser256 in 
response to IGF1 and prevents its nuclear translocation. In myoblasts, FoxO1 inactivation 
reduces CDK inhibitor p27 expression, thus enhancing cell proliferation (166). During 
myogenic differentiation, however, autocrine IGF2 activates Akt, which phosphorylates 
FoxO and allows differentiation to occur (120), suggesting an inhibitory effect of FoxO 
in myogenesis. Consistently, FoxO1 loss of function partially rescued Notch-mediated 
inhibition of myogenic differentiation and increased MyoD expression by down-
regulating Hes1 (140), which suppresses myogenesis by inhibiting MyoD transcription 
(145). Of note, one study by Bois et al. suggested that FoxO1a promoted primary 
myoblast fusion by up-regulating genes involved in cell fusion and extracellular matrix 
remodeling, indicating a positive role of FoxO1 in myogenesis (28). Interestingly, in this 
study, FoxO1 regulation appeared to be independent of PI3K/Akt activity, thus providing 
a potential explanation for the controversies between this study and several others.     
In addition to controlling myogenic differentiation, FoxO transcription factors are major 
modulators of the muscle atrophy program. FoxO1 activates transcription of myostatin, 
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which is a powerful inducer of muscle atrophy in differentiated myotubes in vitro (2). 
Transgenic mice specifically overexpressing FoxO1 in skeletal muscle have reduced 
muscle mass and enhanced lysosomal proteinase cathepsin L expression (132). Another 
member of the FoxO family, FoxO3, functions as a muscle atrophy inducer by acting on 
two major protein degradation pathways, the proteasomal and autophagic-lysosomal 
pathways. Evidence for FoxO3-dependent activation of the ubiquitin-proteasome 
pathway is from the discovery that ubiquitin ligases muscle atrophy F-box (MAFbx) and 
muscle RING finger 1 (MuRF1), which are required for skeletal muscle atrophy (26, 54-
55) are transcriptional targets of FoxO3 (238, 252). FoxO3 is essential for up-regulation 
of autophagy-related genes such as LC3 (169) and is sufficient to induce autophagy in 
skeletal muscle (306), resulting in protein clearance via the autophagic-lysosomal 
pathway.   
Regulation of skeletal muscle growth by IGF-calcineurin signaling 
The calcium-dependent phosphatase calcineurin interacts with IGF signaling to regulate 
skeletal muscle differentiation and hypertrophy. Calcineurin is a serine/threonine protein 
phosphatase that is activated by calcium (94). Activated calcineurin dephosphorylates 
several substrates, including members of the nuclear factor of activated T cell (NFAT) 
transcription factor family, which translocate to the nucleus and activate tissue-specific 
genes (153). Conversely, NFATs can be deactivated and trapped in the cytoplasm 
through phosphorylation by protein kinases such as GSK3β, p38 MAPK and casein 
kinase (17, 296, 308).  
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Calcineurin and NFAT control skeletal muscle differentiation and hypertrophy. Forced 
expression of activated calcineurin enhances myotube formation (73), while calcineurin 
inhibition attenuates myogenesis with reduced myogenic gene expression (94). 
Calcineurin activity is also required for overload-induced muscle hypertrophy (79). 
However, mice that overexpress activated calcineurin in myotubes have normal muscle 
size compared with wild type controls (193), indicating that calcineurin is insufficient to 
induce skeletal muscle hypertrophy in vivo. There are three NFAT genes NFATc1, 
NFATc2 and NFATc3 that are expressed at distinct stages of myogenic differentiation (1). 
NFATc3 is mainly expressed in myoblasts and serves a specialized role in primary 
(embryonic) myogenesis when myoblasts differentiate and fuse into nascent myotubes 
(180). NFATc2 regulates myoblast-myotube fusion in secondary (fetal) myogenesis (117) 
by inducing the secretion of IL4, a fusion-stimulating cytokine that is produced by a 
subset of muscle cells (118). NFATc1 is usually found in nascent and mature myotubes, 
where it has been suggested to participate in the hypertrophic myotube formation (189, 
245).  
The sarcoplasmic reticulum (SR) stores calcium ions and releases them into the 
cytoplasm through L-type calcium channels, which are also known as dihydropyridine 
receptors (DHPR) when the muscle cell is stimulated. As a pore-conducting pathway for 
calcium ions, L-type calcium channels may affect the long-term intracellular calcium 
signaling (72). An array of studies have demonstrated that IGF activates L-type channels 
(72) and increases DHPR α1 subunit expression in skeletal muscle cells (229, 281), 
indicating a potential interaction between IGF and calcium-mediated calcineurin 
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signaling. Indeed, IGF1 induced skeletal muscle hypertrophy through IGF1-calcineurin-
NFATc1 signaling in C2C12 and L6E9 muscle cell lines (189, 245). IGF1 or activated 
calcineurin induced the expression of transcription factor GATA binding protein 2 
(GATA2), which cooperates with hypophosphorylated NFATc1 in myocyte nuclei to 
activate muscle-specific gene transcription (189).  However, it should be noted that a 
potential inhibitory role of calcineurin signaling in muscle hypertrophy has been 
proposed by Glass’s group, who showed that IGF1 and activated Akt antagonized 
calcineurin-mediated dephosphorylation and nuclear translocation of NFATc1 in C2C12 
cells (233).  
 
Role of MAPK signaling cascades in skeletal myogenesis 
Skeletal muscle development is regulated by extracellular stimuli such as growth factors 
that transmit diverse signals into cells to affect the muscle transcription program. The 
mitogen-activated protein kinase signaling modules (MAPKs) play critical roles in the 
process. The MAPK family is categorized into four major groups: c-Jun N terminal 
kinase (JNK), extracellular signal-regulated protein kinase (ERK), p38 stress activated 
protein kinase and extracellular signal-regulated protein kinase 5 (ERK5), all of which 
have been demonstrated to function in mammalian skeletal myogenesis.  
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JNK signaling and myogenesis 
The JNK signaling pathway is activated primarily by environmental stresses, 
inflammatory cytokines and growth factors. These stimuli trigger activation of MAP3Ks 
including apoptosis signal-regulating kinase (ASK), mixed-lineage kinase (MLK), 
MAP/ERK kinase kinase (MEKK) and transforming growth factor β activated kinase 1 
(TAK1), which then activate MAP2K isoforms MKK4 and MKK7 that phosphorylate 
and activate JNK. The activated JNK/SAPKs tanslocate to the nucleus where they 
regulate the activity of multiple transcription factors that are involved in inflammation, 
differentiation, survival, apoptosis and cell migration, such as c-Jun, ATF2, Elk1, 
SMAD4, p53 and NFAT (284). Distinct genes encode for proteins in the JNK family; 
JNK1 and 2 are expressed in various tissues including skeletal muscle while JNK3 is 
specifically expressed in the brain, testis and pancreas (294).  
The role of the JNK signaling pathway in skeletal myogenesis is quite controversial, 
which could be simply reflected by inconsistent assessments of JNK activity during 
myogenic differentiation between distinct studies. Several groups suggested that JNK is 
activated during C2C12 (64), L6E9 (138) and mouse primary myoblast differentiation 
(48) while others showed no alteration (48, 291) or a decrease during this process (212). 
The inhibitory role of JNK pathway in myogenesis has been demonstrated by treating L6 
myoblasts with a JNK/p38 activator anisomycin or ectopic expression of upstream kinase 
MKK7, both of which resulted in impaired myogenin expression and a cytoplasmic 
redistribution of Myf5 in the cells (176). The JNK pathway also functions negatively in 
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stimuli-mediated muscle differentiation. Transforming growth factor β (TGFβ) inhibited 
myogenic differentiation via activation of Rho family proteins Rac1 and Cdc42Hs, which 
were determined earlier to suppress myogenesis by activating JNK pathway (175-176). 
TNFα promoted myoblast proliferation and inhibited differentiation through JNK1, but 
not JNK2 activation-induced expression of leukemia inhibitory factor (LIF), a negative 
mediator of muscle differentiation (3). By using a JNK interacting protein (JIP)-derived 
JNK peptide inhibitor, Strle K et al. showed that JNK activity is required for TNFα 
antagonism of insulin-like growth factor 1 (IGF1)-enhanced muscle growth and 
differentiation (253).  
In contrast, basal JNK activity is indispensable for skeletal muscle differentiation. 
Inhibition of JNK activity by JNK inhibitor II dramatically impaired myotube formation 
of rat L6E9 muscle cells and induced apoptosis accompanied by increased c-Jun and p53 
expression, indicating that JNK is essential for muscle cell survival and differentiation 
(138). Of note, JNK activity also appears insufficient to regulate myogenesis because 
forced JNK activation by overexpressing a constitutively active JNKK had no effect on 
myogenic reporter induction in both C2C12 cells and 10T1/2 fibroblasts that had been 
converted by myoD (291), which is consistent with the unaltered JNK activity that had 
been observed in the cells.   
ERK signaling and myogenesis 
ERK was first discovered as a serine/threonine kinase that phosphorylates microtubule-
associated protein 2 (MAP2) in insulin-stimulated adipocytes and thus was named MAP2 
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kinase (MAP2K) (226). ERK was also known as MAPK, but the name was changed 
because MAPK stands for mitogen-activated protein kinase, which describes additional 
kinase groups. Boulton et al. redesignated MAPK2 as ERK1 in a DNA cloning study (34) 
and characterized two ERK1-related kinases as ERK2 and ERK3 (33). ERK1 and ERK2 
form central components in ERK signaling cascade, which is responsive to various 
extracellular stimuli such as  hormones, growth factors, chemokines, neurotransmitters 
and calcium ions to regulate survival, proliferation, differentiation, development, 
migration and malignant transformation. Despite the involvement of a wide variety of 
receptors and distinct stimuli, ERK signaling cascades usually include small GTP binding 
proteins activation such as Ras and Rap1 by guanine-nucleotide exchange factors (GEFs). 
GTP-bound Ras or Rap1 then activate the MAP3K Raf, which phosphorylates and 
activates the MAP/ERK kinase (MEK), which phosphorylates ERK1/2 (141).       
During skeletal myogenesis, ERK1/2 activity has been described to be either increased 
(48, 100) or decreased (19, 285) with differentiation. Biphasic ERK1/2 activation was 
also observed; ERK1/2 kinase activity is high in undifferentiated myoblasts, is decreased 
with differentiation onset, and increases as differentiation proceeds (291). The potential 
high activities in myoblasts and myotubes imply a dual role of ERK1/2 in muscle 
proliferation and differentiation. Evidence from multiple muscle cell lines has 
demonstrated ERK signaling to be essential for myoblast growth. Serum and growth 
factors such as basic fibroblast growth factor (bFGF) and IGF1 activate ERK1/2 and 
stimulate the mitogenic response via an ERK1/2-dependent pathway in myoblasts (59, 
129, 178, 285). ERK activity prevents cell cycle withdrawal during G1 (111) and ensures 
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the G1 to S phase transition during proliferation (129, 178), probably through up-
regulation of cyclin D (19, 59) and inhibition of cyclin-dependent kinase inhibitor p21 
expression (59).  
Because cell cycle exit is required for myogenic differentiation (4), the critical role of 
ERK1/2 in growth factor-induced proliferation indicates an inhibitory effect on 
myogenesis. Indeed, the ERK1/2 signaling pathway has been suggested to impair muscle 
differentiation by reducing p21 transcription (291), inhibiting myoD expression and 
activation (142, 149, 214, 270), and preventing MEF2 nuclear accumulation (287). 
However, several studies have controversially revealed that ERK1/2 promotes myogenic 
differentiation (100, 154). This controversy was solved using a tetracycline-repressible 
system to overexpress MAPK phosphatase 1 (MKP1), which inactivates ERK1/2 (and 
p38 MAPK and JNK) by dephosphorylation. In this study, Bennett et al. identified 
ERK1/2 as a suppressor at the early stages of differentiation but an inducer of myoblast 
fusion and myotube formation at the later stages in C2C12 cells (19). The biphasic 
requirement for ERK1/2 during myogenesis has been also detected in an independent 
study where the activity of the ERK1/2 upstream activator MEK was targeted (291). The 
stimulatory effect of the ERK1/2 cascade in late differentiation and myocyte fusion is 
likely because of enhanced myoD expression and transcriptional activity (100), increased 
p21 expression (202, 291) and ERK1/2 substrate ribosomal S6 kinase 2 (RSK2)-induced 
nuclear factor of activated T cell c4 (NFATc4) activation (52). Of note, several studies 
have claimed that the ERK signaling module is dispensable for myogenesis because 
treatment of myoblasts with a MEK1 specific inhibitor did not affect the myotube 
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formation or rescue the FGF or oncogenic Ras-induced non-myogenic phenotype (64, 93, 
285). The controversies among these studies may be explained by the distinct ERK 
signaling mediators that were targeted, different experimental conditions and methods, 
and the cell lines that were used.  
p38 MAPK signaling and myogenesis 
The p38 MAPK signaling pathway was initially identified to be activated by 
environmental stresses and pro-inflammatory cytokines. Numerous studies have since 
demonstrated additional functions of this signaling cascade in a wide range of cellular 
processes including cell cycle arrest, apoptosis, cell growth, cell mobility and 
differentiation of several cell types like adipocytes, neurons and myoblasts (137). Various 
extracellular cues such as oxidative stress, cytokines, hormones and growth factors 
stimulate diverse MAP3Ks including MEKK1-4, TAK1, ASK1/2, DLK, MLK2/3 and 
TAO1/2/3 that phosphorylate and activate MKK3, MKK4 or MKK6, which in turn 
phosphorylate and activate the p38 MAPKs. p38 MAPK substrates include transcription 
factors and protein kinases, several of which are involved in development and  
differentiation (161, 301).  
An array of independent studies has demonstrated that the p38 MAPK signaling pathway 
is an essential mediator of skeletal myogenesis. P38 MAPK activity increases 
concomitantly with myogenic differentiation in several muscle cell lines. Deliberate 
activation of p38 MAPKs by ectopic expression of constitutively active MKK6 or 
MEKK1 enhanced myotube formation and muscle-specific gene expression in cultured 
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myoblasts (45, 256, 291), while impaired muscle differentiation was detected in cells 
after p38 MAPK-specific inhibitor treatment or inhibition of upstream activators such as 
MKK3 and TAK1 (45, 64, 256, 291-292, 302). During mouse embryonic development, 
p38 MAPK activity is induced in somites. Inhibition of p38 MAPK signaling using a 
pharmacological inhibitor attenuated myotomal myogenesis in somite explants and in 
embryos in vivo (69). Interference with the p38 MAPK signaling pathway during 
Xenopus Laevis development also caused myogenic defects, further demonstrating a 
conserved and crucial function of p38 signaling modules in skeletal muscle 
differentiation  (136). Despite numerous literatures demonstrating the requirement for 
p38 MAPK activity in myogenesis, an inhibitory function for p38 MAPK signaling in 
this process has also been reported. In a study by Johnson’s group, constitutive MEKK1 
activation dramatically inhibited myotube formation in a p38 MAPK-dependent manner 
in MyoD-converted fibroblasts (203). A later study in C2C12 cells demonstrated that the 
inhibition of p38 MAPK activity at the late stages of muscle differentiation resulted in 
up-regulation of muscle-specific genes (256). Likewise, Weston et al. detected enhanced 
muscle formation by repressing p38 MAPK activity in primary limb mesenchyme 
cultures (283). There are four p38 MAPK isoforms: α, β, γ and δ. The p38α MAPK 
isoform is absolutely crucial for differentiation of primary myoblasts and cultured muscle 
cell lines, whereas a discrepancy exists for the role of other p38 MAPK isoforms in 
myogenic differentiation (151, 212, 277). By using p38 MAPK isoform-specific 
knockout mice and primary myoblasts that were isolated from them, Munoz-Canoves’s 
group discovered that p38β MAPK and p38δ MAPK are dispensable for myogenesis, and 
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p38γ MAPK is only required for optimal cell fusion in vitro, but not necessary for in vivo 
muscle development (212). However, ectopic expression of p38γ MAPK or its inactive 
mutant in C2C12 cells enhanced or impaired myotube formation respectively (151), and 
silencing any of the isoforms with siRNA inhibited C2C12 differentiation (277), 
indicating that the model systems being used should be taken into consideration.    
p38 MAPK regulates myogenic differentiation in multiple ways. First, it triggers cell 
cycle exit in muscle cell cultures, even in rhabdomyosarcoma cells (222), probably 
through CDK p21 induction (45, 64, 291, 302) and inhibition of cyclin expression as well 
as Rb phosphorylation (212-213). Of note, p38α/β MAPK was identified as a molecular 
switch to activate quiescent satellite cells, implying that p38 MAPK promotes 
proliferation during muscle regeneration. Second, the p38 pathway regulates the 
transcriptional activity of MRFs and MEF2 proteins. p38 MAPK stimulates MyoD-
dependent gene transcription indirectly (291, 302). One possible mechanism is through 
MyoD heterodimerization with E47 protein, which is induced by p38 MAPK-mediated 
E47 phosphorylation on Ser140 (160), resulting in functional MyoD binding to muscle-
specific gene promoters (148). However, MEKK1/p38 MAPK signaling may also disrupt 
MyoD/E47 association by phosphorylating E47 and abrogating myotube formation and 
muscle specific-gene transcription (203). p38 MAPK signaling may also activate MyoD 
through p38 MAPK-dependent regulation of MEF2 proteins, which associate with MyoD 
and potentiate its activity. Zester et al. demonstrated that p38 MAPK phosphorylated 
MEF2C to promote its transcriptional activity and a transcriptionally inactive MEF2C 
inhibited MyoD-dependent induction of an MCK reporter (302). Further studies have 
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revealed p38 MAPK mediated-phosphorylation of MEF2A and MEF2D, which enhances 
the transcriptional activities of the MEF2 proteins (291) and MyoD-induced late gene 
expression (211). Much evidence argued against the contribution of p38 MAPK-mediated 
MEF2 phosphorylation to MyoD function stimulation, suggesting that distinct 
mechanisms control MEF2 transcriptional activity, and that there is functional synergy 
between MyoD and MEF2 (196, 222, 291). MRF4 is another p38 MAPK substrate; 
however, its transcriptional activity is negatively regulated by p38 MAPK at the late 
stages of myogenesis, which results in selective repression of muscle-specific gene 
expression and inhibition of precocious myoblast fusion (256). p38 MAPK signaling also 
modulates myogenic differentiation through altering chromatin remodeling on myogenic 
loci. Puri’s group demonstrated that the SWI/SNF (switching/sucrose non-fermenting) 
chromatin remodeling complex is recruited to the myogenin and MCK promoters in a 
p38 MAPK pathway-dependent manner, probably through phosphorylation of the 
SWI/SNF BAF60 subunit by p38 MAPKs (249). This group further demonstrated that 
TNFα-activated p38α MAPK promoted the interaction between YY1 and PRC2 
(polycomb repressive complex 2), resulting in repressive chromatin formation on the 
Pax7 promoter, the down-regulation of which is required before differentiation occurs 
(204). One study in MyoD-converted fibroblasts indicated that p38 MAPK activity also 
facilitates RNA polymerase II recruitment and progression at late muscle-specific 
promoters, and thus enhances gene expression in a MyoD-mediated feed-forward circuit 
(211). In addition, the p38 MAPK pathway positively regulated Myf5 expression in 
Xenopus embryos to ensure normal muscle development (136).  
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Besides modulating myogenic machinery components directly, the p38 MAPK cascade 
also regulates muscle differentiation indirectly through crosstalk with other myogenic 
signaling pathways. A study supporting NFκB as an activator of muscle differentiation 
indicated that p38 MAPK induced NFκB transcriptional activity in C2C12 cells and 
increased IL6 expression, which is sufficient to promote myogenic differentiation (12). 
The p38 MAPK and ERK signaling pathways have also been suggested to antagonize 
each other because p38 MAPK activity inhibition enhanced ERK1/2 activation and vice 
versa in L6E9 muscle cells (139). This interaction could explain the opposite roles of p38 
MAPK and ERK1/2 in cell cycle withdrawal and myoblast differentiation. Another 
interesting relationship between p38 MAPK and JNK pathways has been revealed in one 
study that demonstrated that continuous proliferation was caused by sustained JNK 
activation in primary p38α MAPK-deficient myoblasts (212). Furthermore, the p38 
MAPK and PI3K/Akt/mTOR signaling pathways may crosstalk, which was suggested by 
the discovery that inhibiting any p38 MAPK or the mTOR kinase suppressed the activity 
of the other (64). It is further demonstrated in two independent studies that Akt2 is 
regulated by the p38 MAPK pathway at the protein and mRNA levels during C2C12 
differentiation (44, 98). However, one study indicated that PI3K acted upstream of 
MKK6 to mediate p38 MAPK activation (98), while another reported reciprocal 
communication between the pathways (44).  
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ERK5 signaling and myogenesis 
ERK5, also known as big MAP kinase 1 (BMK1), is the last identified MAPK member to 
date. ERK5 is activated by oxidative and osmotic stresses, certain inflammatory 
cytokines and various growth factors. The MAP3Ks MEKK2 and MEKK3 phosphorylate 
and activate MEK5, the sole upstream MAP2K that activates ERK5. A number of 
transcription factors are ERK5 substrates, including MEF2, c-Myc, c-Fos and Elk4. The 
conventional N-terminal kinase domain and the unique C-terminal transactivation domain 
of ERK5 enable it to maximally activate these transcription factors (195).   
ERK5 is abundant in skeletal muscle and heart (152, 307). Both ERK5 and MEK5 null 
mice displayed defective limb bud development and are embryonic lethal (227, 279, 295). 
Dinev et al. first identified ERK5 as a positive regulator in myogenesis in vitro (77). In 
the study, ERK5 was activated upon differentiation induction in C2C12 cells. Selective 
ERK5 pathway activation enhanced MEF2C transactivation, myogenic gene expression 
and myotube formation, while ERK5 inhibition by antisense RNA resulted in a 
differentiation-defective phenotype, indicating that ERK5 is both required and sufficient 
for myogenesis. MEK5 and ERK5 have been also demonstrated to be essential mediators 
of the pro-myogenic action of IGFII, which activates ERK5 and promotes its nuclear 
translocation (46). A recent study revealed a critical role for ERK5 in muscle cell fusion, 
suggesting a MEK5-ERK5-Sp1-Klf2/4 signaling module that is essential for the fusion 
process (259). However, no alteration of p21, MyoD or MEF2 expression was observed 
in the study, inconsistent with previous observations (46, 77).      
36 
 
 
 
 
Map4k4 
Mitogen activated protein kinase kinase kinase kinase (Map4k4) is a serine/threonine 
protein kinase that belongs to the germinal center kinase GCK-IV group of 
Saccharomyces cerevisiae sterile 20 protein (Ste20) kinases (74). Based on the location 
of kinase domains, Ste20 kinases are divided into two families, p21-activated kinases 
(PAK) and germinal center kinases (GCK), which are further categorized into two and 
eight subfamilies, respectively, according to their distinct structural features in the kinase 
domains and non-catalytic regions (65). Map4k4 contains a NH2-terminal kinase domain 
and a COOH-terminal regulatory domain, a feature of Ste20 kinases in the GCK family.  
Map4k4 was first identified as a mammalian serine/threonine kinase that interacts with 
the SH3 domain of the receptor tyrosine kinase adaptor protein Nck and was termed Nck-
interacting kinase (NIK) (254). Transient overexpression of Map4k4 (NIK) specifically 
activated the SAPK/JNK signaling pathway by interacting with MEKK1 through the 
regulatory domains of both proteins. The human Map4k4 ortholog, known as hepatocyte 
progenitor kinase-like/germinal center kinase-like kinase (HGK), was demonstrated later 
to activate a TAK1, MKK4/7, JNK cellular signaling cascade in 293T cells (297). Other 
studies have also suggested Map4k4 and its orthologs misshapen (msn) in Drosophila 
melanogaster and mig-15 in Caenorabditis elegansas as upstream activators of the JNK 
signaling pathway in various cell types and animal models to regulate morphogenesis, 
development and tumor growth (18, 157, 165, 206, 255). 
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Unlike Msn, which stimulates drosophila embryonic dorsal closure through a JNK 
signaling module (255), mouse Map4k4 plays an essential role in somite formation and 
presomitic mesoderm differentiation into dermomyotome in a JNK-independent manner. 
This was made evident by undisturbed mesodermal and somite development in JNK1- 
and JNK2-deficient mice (293). In this study, presomitic mesodermal cells in Map4k4 
null embryos were observed to fail to migrate away from primitive streak, and it was 
further demonstrated by another study in which Map4k4 has been shown to act upstream 
of p38 MAPK to decrease E-cadherin protein expression and prevent its inhibitory effect 
in mesoderm migration during gastrulation (309). Further studies have identified Map4k4 
as a promigratory kinase (58) and a modulator of cellular transformation, invasion and 
adhesion (106, 290). Consistently, its expression is associated with worse prognosis in 
various cancers (109, 155, 223).  
A genetic screen revealed that Map4k4 positively regulates antigen-mediated T-cell 
responses and is involved in tumor necrosis factor α (TNFα) promoter activation in Jurkat 
cells (167). Silencing Map4k4 in macrophages in vitro attenuated lipopolysaccharide 
(LPS)-induced TNFα expression independently of MAP kinase and NFκB signaling 
pathways (7), which have been demonstrated to regulate TNFα production in 
macrophages (61, 267). More interestingly, Map4k4 suppression in macrophages in vivo 
protected mice from LPS-induced lethality by inhibiting TNFα and interleukin-1β (IL-1β) 
expression (7), suggesting that Map4k4 mediates cytokine production in immune cells. 
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A role for Map4k4 in metabolic regulation of cell function and insulin action has been 
discovered and investigated in recent years. Increased Map4k4 expression was observed 
in abdominal subcutaneous tissue from obese human individuals, correlating with a 
decreased number of preadipocytes that can undergo differentiation (123). Common 
variations in Map4k4 are associated with insulin resistance and pancreatic β cell 
dysfunction in humans (241), indicating a potential role for Map4k4 in diabetes 
pathogenesis. In an RNAi-based screen for regulators of adipocyte function, Map4k4 was 
discovered to inhibit peroxisome proliferator-activated receptor γ (PPARγ) and glucose 
transporter isoform 4 (GLUT4) expression, adipogenesis and insulin-stimulated glucose 
transport (263). The Map4k4-mediated PPARγ suppression was later elucidated to be 
translational downstream of the mammalian target of rapamycin (mTOR) signaling 
pathway (102). Furthermore, TNFα signaling, which down-regulates GLUT4 expression, 
is impaired upon Map4k4 silencing in cultured adipocytes, indicating that Map4k4 is 
required for optimal TNFα action (263). Interestingly, TNFα selectively stimulates 
Map4k4 expression by activating transcription factors c-Jun and ATF2 through TNFα 
receptor 1 (TNFR1) signaling cascades (266).  
Map4k4 also functions in muscle to blunt insulin sensitivity. Map4k4 gene silencing in 
primary human skeletal muscle cells prevented TNFα-induced insulin resistance by 
impeding excessive activation of JNK and ERK signaling pathways as well as IRS-1 
phosphorylation (36). In rat pancreatic β cells, TNFα inhibits glucose-stimulated insulin 
secretion by decreasing IRS-2 expression and glucose-induced phosphorylation of Akt, 
AS160, the insulin receptor and ERK. In these cells, Map4k4 activated p70S6K, JNK, 
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p38 MAPK, and NF-κB. Map4k4 depletion rescued the β cells from the detrimental 
effects of TNFα on insulin secretion and signaling as well as p70S6K and JNK activation, 
while p38 and NF-κB phosphorylation was unaffected (35).  
 
Specific Aims 
An array of studies has identified Map4k4 as an upstream regulator of members of 
MAPK family including p38 MAPK, JNK and ERK in multiple cell lines. Furthermore, 
Map4k4 was discovered to regulate PPARγ translation through modulating 
mTOR/4EBP1 signaling pathway in cultured adipocytes. Both MAPKs and mTOR have 
been demonstrated to play important roles in skeletal muscle differentiation. mTOR is 
also a component of IGF/Akt signaling, which promotes skeletal muscle development 
and hypertrophy though regulating multiple downstream effectors including mTOR, 
GSK3β and FoxO. Given the regulatory interactions between Map4k4 and MAPKs as 
well as mTOR, and the involvement of the latter proteins in skeletal myogenesis, I aimed 
to test whether Map4k4 regulates skeletal muscle differentiation as its identified 
downstream effectors do. To address this RNAi and adenovirus-mediated overexpression 
strategy were employed for an in vitro study in murine muscle cell line C2C12. The 
specific aims of this study were:  
(1) To determine the role of Map4k4 in skeletal muscle differentiation. 
(2) To identify the signaling pathways that Map4k4 may participate in to regulate the 
myogenic process.     
 
 
CHAPTER II: Identification of Map4k4 as a novel suppressor 
of skeletal muscle 
 
Disclaimer: 
All experiments were performed by the author except for Figure 2.1A and Figure 2.3B 
which were done in collaboration with Shinya U. Amano. Figure 2.1C was done in 
collaboration with Rachel J. Roth Flach.  Anil Chawla generated the construct for Myf5 
overexpression. Dr. Diane L. Barber provided the adenoviruses expressing GFP, native 
Map4k4 and kinase-inactive Map4k4 mutant. 
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Abstract 
Myoblast differentiation into mature myotubes is a critical step in the development and 
repair of human skeletal muscle. Here we show that siRNA-based silencing of the Ste20-
like mitogen-activated protein 4 kinase 4 (Map4k4) in C2C12 myoblasts markedly 
enhances expression of myogenic differentiation genes, myoblast fusion and myotube 
diameter. In contrast, adenovirus-mediated expression of native Map4k4 in C2C12 cells 
attenuates each of these processes, indicating Map4k4 is a negative regulator of 
myogenic differentiation and hypertrophy. Expressing a Map4k4 kinase-inactive mutant 
enhances myotube formation, suggesting kinase activity of Map4k4 is essential for its 
inhibition of muscle differentiation. Map4k4 regulation of myogenesis is unlikely to be 
mediated by classic MAPK signaling pathways because no significant difference in 
phosphorylation of ERK, p38 or JNK is observed in Map4k4-silenced cells. Furthermore, 
silencing of these other MAPKs does not result in a hypertrophic myotube phenotype as 
does Map4k4 depletion. Uniquely, Map4k4 silencing up-regulates the expression of 
myogenic regulatory factor Myf5, depletion of which inhibits myogenesis. Furthermore, 
Myf5 is required for enhancement of myotube formation in Map4k4-silenced cells, while 
Myf5 overexpression rescues Map4k4-mediated inhibition of myogenic differentiation. 
These results demonstrate that Map4k4 is a novel suppressor of skeletal muscle 
differentiation, acting through a Myf5-dependent mechanism.  
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Introduction 
Skeletal muscle differentiation is a highly coordinated multistep process in which 
mononucleated myoblasts first withdraw from the cell cycle in response to extracelluar 
cues, differentiate into post-mitotic myocytes (early differentiation), and subsequently 
fuse into multinucleated myotubes (late differentiation) which finally bundle to form 
mature muscle fibers (terminal differentiation). This process is elaborately controlled by 
activation of Myf5, MyoD, myogenin and MRF4, four myogenic regulatory factors 
(MRFs) belonging to a family of basic helix-loop-helix transcription factors. During 
myogenesis, MRFs are activated and operate in concert with other transcriptional 
regulators such as myocyte enhancer factor 2 (MEF2) in a coordinated manner to regulate 
the transcription of muscle-specific genes including myosin heavy chain (MyHC) and 
muscle creatine kinase (MCK) (40, 181, 200). Previous studies have confirmed Myf5 and 
MyoD as muscle determination factors that are mainly expressed in undifferentiated 
myoblasts and differentiating myocytes, while myogenin is activated in early 
differentiation (21). Mrf4 has been shown to be transiently expressed during 
somitogenesis and later fiber maturation (115), playing roles in myogenic lineage 
commitment (134) as well as myoblast fusion and differentiation (256-257).  
Mitogen-activated protein kinases (MAPKs) are components of serine/threonine protein 
kinase cascades that respond to extracellular stimuli and regulate essential cellular 
functions such as proliferation (305), differentiation (5-6, 32) and apoptosis (275). The 
MAPK family is categorized into three main groups: p38 stress activated protein kinase, 
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c-Jun N terminal kinase (JNK) and extracellular signal-regulated protein kinase (ERK) 
(128), all of which have been demonstrated to be involved in mammalian skeletal 
myogenesis (141, 161). The exploration of new upstream kinases that modulate the 
downstream effector MAPKs identified mitogen activated protein kinase kinase kinase 
kinase (MAP4K4), a serine/threonine protein kinase that belongs to the germinal center 
kinase GCK-IV group of Saccharomyces cerevisiae sterile 20 protein (Ste20) kinases 
(65). Map4k4 may activate the JNK signaling pathway in some cell types and mediate 
cancer cell proliferation, apoptosis and motility (58, 157). It was found to play an 
essential role in development (293) and it has been shown to be critical for mesoderm 
migration during gastrulation by acting upstream of p38 MAPK (309). In an RNAi-based 
screen for regulators of adipocyte function, we discovered that Map4k4 down-regulates 
expression of peroxisome proliferator-activated receptor γ (PPARγ), a transcription factor 
that is essential for adipocyte differentiation and function (263). Cell size, insulin-
mediated glucose transport and triglyceride content were found to be significantly 
increased upon Map4k4 silencing in cultured adipocytes (102), indicating that Map4k4 is 
a negative regulator of insulin-stimulated lipogenesis and adipose hypertrophy.  
More recently it was found that Map4k4 also functions in muscle to enhance insulin 
sensitivity (7). Map4k4 gene silencing in primary human skeletal muscle cells prevented 
tumor necrosis factor α (TNFα)-induced insulin resistance (36). However, the role of 
Map4k4 in skeletal myogenesis has not been addressed. In the present study we used 
C2C12 murine myoblasts to investigate the function of Map4k4 on myogenic processes. 
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We demonstrate that Map4k4 acts upstream of Myf5 as a negative regulator of skeletal 
muscle differentiation.  
Materials and Methods 
Molecular biology. Mouse Myf5 clone (accession number: NM_008656) was purchased 
from Open Biosystems. The coding regions of Myf5 gene was PCR-amplified and cloned 
into pCMV plasmid carrying three N-terminal hemaggutinin (HA) tags (pCMV-3HA) to 
create a N-terminally HA-tagged Myf5 construct. Primers used to amplify PCR 
fragments of Myf5 coding region were as follows: 5’ fragment: 
CGATCGCCACGCGTATCTCGAGCTATGGACATGACGGACGGCTGCCAGTTCT
CCCCT; 3’ fragment: GCGTACGGATCCGTCGACTCATAATA 
CGTGATAGATAAGTCTGG AGCTGGAGGGTCC.  
Cell culture and transfection. Mouse C2C12 myoblasts (American Type Culture 
Collection) were cultured in growth medium (GM) consisting of Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin at 37°C with 5% CO2. To induce differentiation, 95% confluent 
cells were placed in differentiation medium (DM) consisting of DMEM with 2% horse 
serum. Multinucleated myotubes were evident after 3 days of differentiation. For siRNA 
transfection, C2C12 myoblasts cultured in growth medium were transfected with 50 pmol 
siRNA using Lipofectatmine RNAiMAX (Invitrogen) according to the manufacturer’s 
instruction for reverse transfection. Twenty-four hours later, cells were switched to DM 
and cultured for the indicated times before harvesting. To transfect siRNA in 
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differentiated myotubes, siRNA/endoporter complexes were used as described previously 
(265). Briefly, 50 pmol of siRNA was incubated with 2.5 nmol of endoporter (Gene 
Tools) in phosphate buffered saline (PBS) for 15 minutes and added to cells. All of the 
siRNA was purchased from Dharmacon (Lafayette, CO). For plasmid transfection, GM-
cultured C2C12 myoblasts were transfected with 2 µg of plasmids using Lipofectatmine 
2000 (Invitrogen) according to the manufacturer’s instruction for reverse transfection. 
Twenty-four hours later, cells were switched to DM and cultured for the indicated times 
before harvesting. 
Adenovirus infection. C2C12 myoblasts were grown until 90% confluence and were 
then infected with GFP control virus, Map4k4 wild type virus or Map4k4 D152N virus at 
the dose of 104 virus particles per cell for 18 hours in GM before differentiation. 72 hours 
post-differentiation, cells were fixed for immunofluorescence or harvested for western 
blotting. All the adenoviruses were gifts from Dr. Diane L. Barber (Department of Cell 
and Tissue Biology, University of California, San Francisco, CA)   
Myotube analysis. Myotube nuclei were counted in approximately 100 randomly chosen 
MyHC-positive cells containing three or more nuclei. Myotubes were categorized into 
three groups (3-6 nuclei, 7-15 nuclei and more than 15 nuclei per myotube) and were 
expressed as a percentage of total myotube number. The fusion index was calculated as 
the ratio of nuclei in MyHC-positive myotubes to the total number of nuclei in the field in 
five random fields. To analyze myotube diameter, five fields were chosen randomly, and 
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three myotubes were measured per field. The average diameter per myotube was 
calculated as the mean of three measurements taken along the long axis of the myotube.  
Isolation of mouse satellite cells. Satellite cells were isolated from 6-8 week old 
C57B6/J mice by FACS sorting as described previously (209). Briefly, skeletal muscles 
were digested with collagenase B (10 mg/ml, Roche) and dispase II (2.4 U/ml, Roche), 
filtered through 250, 100 and 40 µm nylon meshes successively. The resulting 
mononuclear cells were incubated with anti-mouse Integrin α7 clone 3C12 (MBL) and 
biotin anti-mouse CD34 (eBioscience) antibodies for 20 minutes and then stained with 
hoechst 33258 (sigma), PE anti-mouse CD11b (eBiosciences), PE anti-mouse CD45 
(eBiosciences), PE anti-mouse Ly-6A-E (Sca1, BD Bioscience), PE anti-rat CD31 (BD 
Bioscience), streptavidin-APC-Cy7 (BD Bioscience) antibodies. Integrin 
α7+CD34+CD31-CD11b-CD45-Sca1- cells were considered as satellite cells and sorted by 
BD FACS Aria II.    
Western blotting. Cells were solubilized with ice-cold lysis buffer (20 mM HEPES, pH 
7.2, 100 mM NaCl, 1mM EDTA, 100 mM PMSF, 0.01% Triton X-100, 1% SDS and 
Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific)) and protein 
concentrations were assessed by BCA assay (Thermo Scientific). Equal amounts of 
protein were loaded on 8.5% SDS-polyacrylamide gels and transferred to nitrocellulose 
membranes. The following antibodies were used: anti-Map4k4 (Bethyl), anti-Myf5 (sc-
20, Santa Cruz), anti-MyoD (BD biosciences), anti-Mef2C (Cell Signaling), myogenin 
F5D (Developmental Studies Hybridoma Bank (DSHB), University of Iowa), sarcomeric 
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myosin heavy chain (MHC) MF20 (DSHB, University of Iowa), anti-phospho-p38 (Cell 
Signaling), anti-total p38α (Cell Signaling), anti-phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204) (Cell Signaling), anti-p44/42 MAPK (ERK1/2) (Santa Cruz), anti-
phospho-SAPK/JNK (Thr183/Tyr185) (Cell Signaling) and anti-SAPK/ JNK (Cell 
Signaling). 
Immunofluorescence microscopy. Cells grown on glass coverslips were fixed with 4% 
formaldehyde and blocked in PBS containing 2% goat serum (Invitrogen), 1% bovine 
serum albumin (Sigma), 0.1% Tween 20 and 0.05% Triton X-100 (American 
Bioanalytical) for 1 hour at room temperature. The cells were then incubated with MF20 
mAb against MHC (1:40, DSHB) for 2.5 hours and subsequently with Alexa 488 or 
Alexa 594-conjugated secondary antibody (1:200, Invitrogen) for 1 hour at room 
temperature. Cells were mounted with ProLong Gold antifade reagent with DAPI 
(Invitrogen). Images were obtained using a Zeiss Axiovert 200 inverted microscope 
equipped with a Zeiss AxioCam HR CCD camera. 
EdU incorporation test. C2C12 cells were were incubated for 1 hour with 10 uM EdU 
(Invitrogen) before harvesting. Cells were washed once with 1% BSA and 0.09% NaN3 
(FACS buffer) before fixation with Fixation/permeabilization buffer (eBioscience) and 
permeabilized with permeabilization buffer (eBioscience). EdU was chemically 
conjugated to Alexa 405 fluorophore according to the instructions of the manufacturer 
(Invitrogen). Sample data were acquired on a BD LSRII (BD Biosciences) and analyzed 
with FlowJo software (Tree Star). 
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Creatine kinase activity assay. Cells were lysed in ice-cold lysis buffer (20 mM HEPES, 
pH 7.2, 100 mM NaCl, 1mM EDTA, 100 mM PMSF, 0.01% Triton X-100 and protease 
and phosphatase inhibitor cocktail). Lysates were centrifuged at 14000 × g for 10 min at 
4°C and the supernatants were used immediately for creatine kinase (CK) activity assay. 
CK activity was measured using a spectrophotometric-based kit (Stanbio Laboratory, 
Boerne, TX, USA) according to the manufacturer’s instructions. Specific CK activity was 
calculated by normalizing to total protein content.  
Map4k4 kinase activity assay.  Cells were solubilized with ice-cold lysis buffer (50 mM 
Tris, pH 7.4, 100 mM NaCl, 5 mM EDTA, 1% NP-40, 0.1% deoxcholic acid and 
protease and phosphatase inhibitor cocktail). Cell lysates were immunoprecipitated with 
anti-Map4k4 antibody (Bethyl). Myelin basic protein (MBP) (1 µg) and 10 µCi of [γ-
32P]-ATP were added into the immunoprecipitates and incubated for 30 min at 30°C in 
kinase buffer ( 20 mM  HEPES, 10 nM MgCl2, 1 mM DTT and protease and phosphatase 
inhibitor cocktail). Samples were separated by 12% SDS-PAGE and visualized by 
autoradiography. Map4k4 kinase activities were determined by normalizing the 
radioactivity of 32P-labeled MBP to the amount of immunoprecipitated Map4k4 protein 
as detected by Western blot.  
Isolation of RNA and Real Time PCR. RNA isolation was performed according to the 
Trizol Reagent Protocol (Invitrogen). cDNA was synthesized from 1.5 μg of total RNA 
using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules CA) according to the 
manufacturer’s instructions. For real time PCR, synthesized cDNA and iQ SYBR Green 
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Supermix were run on the MyIQ Realtime PCR System (Bio-Rad) with following primer 
pairs: Map4k4 5’-CATCTCCAGGGAAATCCTCAGG-3’, Map4k4 5’-
TTCTGTAGTCGTAAGTGGCGTCTG-3’; Myf5 5’-TATGAAGGCTCCTGTATCCC-
3’, Myf5 5’-ACGTGCTCCTCATCGTCTG-3’. 36B4 was used as an internal loading 
control. Relative gene expression was determined using the ΔCt method (159).  
Statistics. The statistical significance of the differences in the means of experimental 
groups was determined by two-tailed student’s t test using Microsoft EXCEL. The data 
were presented as the means ± SEM. A p value of <0.05 was considered significant.  
Results 
Map4k4 expression and protein kinase activity are decreased during skeletal muscle 
differentiation. 
To determine whether Map4k4 may play a role in muscle differentiation, we first 
examined Map4k4 expression in primary mouse satellite cells and mature muscle fibers. 
Adult satellite cells are considered to be progenitor cells of somitic origin in skeletal 
muscle development (101). Real-Time PCR (RT-PCR) analysis revealed a 4-fold 
decrease in Map4k4 expression in mouse quadriceps compared with purified satellite 
cells isolated by fluorescence-activated cell sorting from the same mice (Fig 2.1A). We 
also investigated Map4k4 expression during differentiation of C2C12 cells, a well-
established cell line that is derived from mouse satellite cells and faithfully mimics 
skeletal muscle differentiation process in vitro. A reduction of Map4k4 protein levels was 
detected during C2C12 myogenic differentiation by Western blot, concomitant with the 
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increased expression of differentiation markers myogenin and myosin heavy chain 
(MyHC; Fig 2.1B). Furthermore, we measured Map4k4 protein kinase activity during 
C2C12 differentiation, determining it was highest in confluent myoblasts and decreased 
dramatically after 24 hours of differentiation (Fig 2.1C). These results indicated that 
Map4k4 is dynamically regulated during skeletal muscle differentiation, suggesting a 
potential role for Map4k4 in muscle development.  
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Figure 2.1 Expression and kinase catalytic activity of Map4k4 during skeletal muscle 
differentiation. (A) RT-PCR analysis of Map4k4 expression in isolated mouse satellite 
cells vs. quadriceps. Data represent mean ± SEM from three independent experiments. (B) 
Expression of Map4k4 during C2C12 myogenic differentiation.  Densitometry was 
representative of mean ± SEM from four independent experiments. (C) C2C12 myoblasts 
were incubated in differentiation medium (DM) for the indicated times. Map4k4 kinase 
activity at each time point was assessed by kinase assay and immunoblotting. Results 
represent mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.  
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Map4k4 silencing promotes skeletal muscle differentiation.  
To explore the function of Map4k4 in myogenic differentiation, we used siRNA directed 
against Map4k4 to deplete the protein kinase in C2C12 myoblasts and monitored 
morphological differences during cell differentiation. Map4k4 silencing resulted in 
significant sustained reduction of Map4k4 protein throughout differentiation and 
formation of larger myotubes after 48 hours in differentiation medium (DM) (Fig. 2.2A). 
Enhanced muscle cell fusion was observed in Map4k4-silenced cells on differentiation 
day 3, as there was a shift toward myotubes containing more nuclei per myotube (Fig. 
2.2B) and an increased fusion index (Fig. 2.2C). Map4k4 silencing also resulted in a 70% 
increase of cell diameter in day 3 myotubes (Fig 2.2D), likely due to enhanced myoblast 
fusion. Similar nuclei numbers in random microscopic fields were detected in Map4k4-
silenced myoblasts and myocytes (Fig 2.3A), excluding the possibility that the hyper-
nucleated myotubes with increased size resulted from an increased number of 
undifferentiated myoblasts available for the fusion process. 
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Figure 2.2 Map4k4 silencing promotes myotube formation in C2C12 cells. C2C12 
myoblasts were transfected with scrambled siRNA or siRNA against Map4k4. 24 h later 
the cells were transferred DM for the indicated times. (A) Top panel, knockdown 
efficiency of Map4k4 was determined by immunoblot. Bottom panels, cells were fixed 
and immunostained for MyHC and myoblast differentiation was observed by 
fluorescence microscopy (green, MyHC; blue, DAPI, 100×). Data is representative of at 
least three independent experiments. (B) Fraction of myotubes with the indicated number 
of nuclei were quantified in 100 randomly chosen myotubes after 72 h in DM. (C) The 
fusion index for day 3 myotubes was calculated from the ratio of nuclei number in 
MyHC-positive myotubes versus the total number of nuclei in one field in five random 
microscopic fields. (D) Myotube diameters were measured in day 3 myotubes. Results 
represent mean ± SEM from three independent experiments. *** p <0.001. 
54 
 
54 
 
 
 
 
Figure 2.3 Map4k4 silencing has no effect on C2C12 myoblast proliferation. (A) 
C2C12 myoblasts were transfected with scrambled or Map4k4 siRNA. 24 hours later, the 
cells were cultured for additional 24 hours in GM or transferred to DM. Nuclei were 
counted after 24 hours in GM or 24 hours and 48 hours in DM. The values were obtained 
after counting at least 6 microscopic fields in duplicate samples. (B) C2C12 myoblasts 
were infected with adenoviruses expressing GFP, wild type Map4k4 or Map4k4 kinase-
inactive mutant D152N for 24 hours. Factions of GFP-positive cells in S phase in GM (0 
h) and in DM for 24 hours were analyzed by FACS after staining with EdU. Data 
represent mean ± SEM for triplicates in two independent experiments. 
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We further studied the differentiation program by examining the expression of muscle 
differentiation markers. No significant changes in MyoD protein levels were detected in 
Map4k4-silenced cells compared with scrambled siRNA-transfected controls during 
differentiation (Fig 2.4, A and B). However, significant transient increases in myogenin 
and Mef2C expression were detected in Map4k4-silenced cells at 16 hours and 48 hours 
of differentiation respectively (Fig 2.4, A and B). MyHC expression starts in a population 
of mononuclear myoblasts and rapidly increases with myoblast fusion during late 
myogenesis ((194) and Fig 2.4A). Map4k4 silencing enhanced MyHC expression during 
late C2C12 differentiation, although the increase was only significant at 48 hours of 
differentiation with trends toward increased expression at later time points (Fig 2.4, A 
and B). MCK activity, a later marker of skeletal muscle cell differentiation, was increased 
by 45% in Map4k4-silenced cells at day 3 of differentiation. These results suggest that 
silencing of Map4k4 enhances myotube formation and promotes skeletal myogenic 
differentiation.  
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Figure 2.4 Map4k4 silencing enhances C2C12 myogenic differentiation. C2C12 
myoblasts were transfected with scrambled or Map4k4 siRNA. Cells were transferred to 
DM 24 h after transfection and differentiated for the indicated times. (A) Expression of 
myogenic differentiation proteins was assayed by immunoblotting with the indicated 
antibodies. Data is representative of three independent experiments. (B) Densitometric 
analysis from western blot in (A). (C) Creatine kinase (CK) activities of transfected cells 
were measured after 3 days in DM. Data represent mean ± SEM from three independent 
experiments. * p < 0.05, *** p < 0.001.  
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Inhibition of myogenic differentiation by Map4k4 requires its kinase activity.  
Since suppression of Map4k4 expression enhanced skeletal muscle differentiation, we 
hypothesized that Map4k4 overexpression would have the opposite effect. To test this, 
adenoviruses expressing GFP control (AdGFP) or wildtype (wt) Map4k4 (AdMap4k4 wt) 
(16) were used to infect C2C12 myoblasts for 18 hours prior to differentiation. 
Overexpression of wt Map4k4 impeded MyHC-positive myotube formation (Fig 2.5A) 
and myoblast fusion (Fig 2.5B) within 72 hours of serum deprivation. Western blot 
analysis confirmed that the expression of Mef2c and late myogenic differentiation marker 
gene MyHC was inhibited in wt Map4k4-overexpressing cells (Fig 2.5C). We also 
assessed the effect of a Map4k4 kinase-inactive mutant on myogenic differentiation. 
C2C12 myoblasts were infected with adenoviruses expressing Map4k4 D152N, a kinase-
inactive mutant of Map4k4 (AdMap4k4 D152N) (16) and were induced to differentiate 
into myotubes for 72 hours. Interestingly, Map4k4 D152N overexpression caused the 
formation of larger myotubes and a substantial increase in myoblast fusion (Fig 2.5, A 
and B), similar to the results of the Map4k4 knockdown experiments (Fig 2.5, A and C). 
An increase in Mef2c and MyHC expression was also observed in Map4k4 D152N-
overexpressing cells (Fig 2.5C). These data suggest that the Map4k4 kinase-inactive 
mutant functions as a dominant-negative inhibitor, possibly by competing with the 
functional endogenous Map4k4 in C2C12 cells, and that Map4k4 kinase activity is 
required to repress skeletal muscle differentiation. Furthermore, Map4k4 does not 
regulate myogenic differentiation through affecting myoblast proliferation, because no 
change in the percentage of EdU-positive cells was observed in wt or kinase-inactive 
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Map4k4-overexpressing C2C12 cells (Fig 2.3B), consistent with the unaltered nuclei 
numbers in myoblasts and myocytes upon Map4k4 silencing (Fig 2.3A). 
 
 
Figure 2.5 Map4k4 kinase activity is required for its inhibition of C2C12 myogenic 
differentiation. C2C12 myoblasts were infected with adenoviruses expressing GFP, wild 
type Map4k4 or Map4k4 kinase-inactive mutant D152N and differentiated for 72h. (A) 
Cells were immunostained with anti-MyHC antibody. Images were photographed by 
fluorescence microscopy (red, MyHC; blue, DAPI, 100×). (B) Quantitative analysis of 
myogenic conversion scored by fusion index. Data represent mean ± SEM from two 
independent experiments. *** p < 0.001. (C) Immunoblot analysis of Map4k4 and 
myogenic markers. Data is representative of three independent experiments.  
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Map4k4 does not regulate myogenic differentiation through canonical MAPK 
signaling pathways.  
In other systems Map4k4 has been described as an upstream effector in JNK, ERK and 
p38 signaling pathways. These pathways are also reportedly involved in skeletal muscle 
differentiation, thus it seemed possible that Map4k4 regulates myogenic differentiation 
through these canonical MAPK pathways. To assess this hypothesis, we used siRNA to 
suppress MAPK expression separately or in combination in C2C12 myoblasts and 
monitored myogenic differentiation by visualizing MyHC-positive myotube formation. 
We posited that if Map4k4 functions upstream in the respective signaling pathway to 
regulate myogenesis, then silencing of the downstream effectors would result in a similar 
phenotype as Map4k4 silencing. However, depletion of p38α abolished myogenic 
differentiation because few p38α-silenced cells fused into multinuclear myotubes (Fig 
2.6A), consistent with the conclusion derived from previous studies that p38α is critical 
for skeletal myogenesis (64, 291, 302). Other reports have shown that basal JNK activity 
is essential for regulation of skeletal muscle differentiation and inhibition of JNK 
activation inhibited myogenesis by inducing myoblast apoptosis (138). We suppressed 
JNK1 expression in myoblasts and observed a minimal effect of JNK1 silencing on 
myotube formation under our experimental conditions. However, JNK2 or JNK1/2 
silencing in combination inhibited myogenic differentiation, as shown by reduced 
myotube formation (Fig 2.6A). ERK1/2 is essential for myoblast proliferation, and is 
inhibitory to early differentiation, but is also required for myocyte fusion. Inhibition of 
ERK activity early in myogenesis promotes differentiation, whereas later inhibition 
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impedes differentiation (291). In our study, ERK1 silencing in C2C12 myoblasts 
promoted myotube formation while knockdown of ERK2 resulted in the formation of 
smaller myotubes. Myotubes differentiated from ERK1 and ERK2 double knock down 
myoblasts had modestly decreased size compared to the ones differentiated from the 
scrambled siRNA transfected control (Fig 2.6A). These results revealed that Map4k4 
functions differently on myogenic differentiation than the canonical MAPK pathways. 
This conclusion was further confirmed by measurement of phosphorylation levels of the 
MAPKs during differentiation. No significant changes in p38α, ERK1/2 or JNK1/2 
phosphorylation were observed in Map4k4-silenced cells (Fig 2.6B), indicating that 
Map4k4 failed to regulate their activities during myogenic differentiation.  
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Figure 2.6 Map4k4 silencing does not promote skeletal muscle differentiation 
through canonical MAPK signaling pathways. C2C12 myoblasts were transfected with 
scrambled siRNA or siRNA against Map4k4, p38α, JNK1, JNK2, JNK1+JNK2, ERK1, 
ERK2 or ERK1+ERK2. Cells were transferred to DM 24 h after differentiation and 
incubated for 72h. (A) Left panels, myoblast differentiation was observed by 
immunostaining for MyHC expression (50×). Right panels, knockdown efficiency of the 
MAP kinases was determined by western blot. (B) C2C12 myoblasts were transfected 
with scrambled or Map4k4 siRNA. Cells were transferred to DM 24 h after transfection 
and incubated for the indicated times. Lysates were immunoblotted with the indicated 
antibodies. Densitometric analysis represents mean ± SEM from three independent 
experiments.  
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Map4k4 functions mainly at the early stage of myogenic differentiation.  
To investigate the stages of myogenic differentiation in which Map4k4 functions, C2C12 
cells were transfected with scrambled siRNA or siRNA targeting Map4k4 at multiple 
stages of differentiation and for variable periods of time (Fig 2.7A, right panels), and 
myotube formation was assessed on day 4 after initiation of differentiation by measuring 
the fusion index. In these experiments 90% of Map4k4 proteins were depleted in 
myotubes at this day 4 point in response to transfections of Map4k4 siRNA at the 
different time points shown (Fig 2.7B). Map4k4 silencing in myoblasts (day -1) provoked 
the most robust myotube formation (Fig 2.7A, upper left panels), as the fusion index in 
Map4k4-silenced cells was 60% higher than in the control cells on day 4 (Fig 2.7C). 
Map4k4 depletion at day 1 in myocytes that are about to enter the late stage of 
differentiation still resulted in larger myotubes and increased myoblast fusion compared 
to the control cells. However, the promotion of myotube formation was less than that 
resulted from Map4k4 silencing at earlier stages in myoblasts differentiation (Fig 2.7, A, 
middle left panels and C). When siRNA against Map4k4 was transfected into day 2 
myotubes, coincident with onset of terminal differentiation, the myotubes showed even 
smaller changes in size or fusion compared to the results obtained from Map4k4 
suppression in myoblasts and day 1 myocytes (Fig 2.7, A, lower left panels and C). These 
results indicate that Map4k4 functions in multiple stages of muscle differentiation, but 
the enhanced myotube formation observed in Map4k4-depleted cells at later stages of 
differentiation mainly results from a role that Map4k4 plays at the onset of myogenic 
differentiation. That Map4k4 apparently plays an early role in the process is also 
64 
 
64 
consistent with the higher Map4k4 kinase activity at the early stage of muscle 
differentiation (Fig 2.1B).  
 
 
Figure 2.7 Map4k4 functions mainly at the early stage of myogenic differentiation. 
C2C12 myoblasts were transfected with scrambled or Map4k4 siRNA at different stages 
of differentiation for the indicated time periods. (A) Left panels, cells were fixed and 
immunostained for MyHC (green) after 4 days in DM (100×). Right panels, schematics 
of the time course of siRNA application. (B) Knockdown efficiency of Map4k4 was 
determined by immunoblot. (C) The fusion index was calculated by dividing the number 
of nuclei in MHC-positive cells by the total number of nuclei in that field. Data represent 
mean ± SEM from two independent experiments. ** p <0.01, *** p < 0.001. 
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Map4k4 regulates myogenic differentiation in a Myf5-dependent manner. 
Among the four myogenic regulatory factors, Myf5 and MyoD regulate the early stage of 
skeletal muscle differentiation. Because no change in MyoD expression was detected in 
Map4k4-silenced cells during differentiation (Fig 2.4, A and B), we examined expression 
Myf5 expression by RT-PCR and Western blot. In cells treated with scrambled siRNA, 
Myf5 expression increased in early differentiation, peaked at 24 hours, and then 
decreased (Fig 2.8, A and B). Map4k4 silencing increased Myf5 mRNA transcripts by 
1.4-fold within 16 hours of myogenic differentiation (Fig 2.8A). More dramatically, a 
three-fold increase in Myf5 protein levels was detected in Map4k4-depleted 
undifferentiated myoblasts and myocytes at the early stage of differentiation (Fig 2.8B).    
To determine whether the increase in Myf5 protein levels is essential for the enhanced 
myogenic differentiation that is found after Map4k4 depletion, we performed double 
knockdown experiments to suppress Map4k4 and Myf5 expression simultaneously in 
C2C12 myoblasts, and examined differentiation by microscopic analysis and Western 
blot. As expected, Map4k4 knockdown promoted myogenic differentiation and Myf5 
expression (Fig 2.9). In contrast, Myf5 silencing impeded myogenic differentiation as 
shown by reduced myotube formation (Fig 2.9A), decreased myoblast fusion (Fig 2.9B) 
and lower expression of myogenin, Mef2C and MyHC during differentiation (Fig 2.9C). 
Importantly, when compared with Map4k4 suppression alone, smaller myotubes with less 
fusion and myogenic differentiation factor expression were observed when Map4k4 and 
Myf5 were silenced simultaneously (Fig 2.9), indicating that reduced levels of Myf5 
expression partially inhibit the effects of Map4k4 silencing on myogenic differentiation.  
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Figure 2.8 Map4k4 silencing increases Myf5 expression. C2C12 myoblasts were 
transfected with scrambled or Map4k4 siRNA and transferred to DM for the indicated 
times 24 h post transfection. (A) Myf5 mRNA level was determined by Real-Time PCR. 
(B) Upper panel, Myf5 protein level was determined by immunoblot. Lower panel, 
densitometry of Myf5 as normalized to α-tubulin. Data is represented as the mean ± SEM 
of three independent experiments. * p < 0.05, ** p < 0.01.  
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Figure 2.9 Suppression of Myf5 impairs Map4k4 silencing-enhanced myogenic 
differentiation. C2C12 myoblasts were transfected with scrambled siRNA, siRNA 
against Map4k4, Myf5 or a combination of both.  (A) Cells were fixed and 
immunostained for MyHC (green) at day 3 after differentiation and myogenic conversion 
was observed by fluorescence microscopy (50× and 100×). (B) The fusion index was 
calculated for transfected cells after 3 days in DM. Results represent mean ± SEM from 
three independent experiments. *** p < 0.001. (C) Immunoblot of myogenic 
differentiation proteins. Data is representative of three independent experiments.  
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To further demonstrate that Myf5 is a downstream effector of Map4k4 signaling in the 
regulation of skeletal muscle differentiation, we overexpressed Map4k4 and Myf5 
simultaneously in C2C12 myoblasts, and examined muscle differentiation by microscopy 
and immunoblotting. Expression of native Map4k4 protein kinase inhibited C2C12 
myogenic differentiation while Myf5 expression robustly enhanced myotube formation 
(Fig 2.10, A and B) and late differentiation marker expression (Fig 2.10C). Interestingly, 
Myf5 expression significantly reversed the inhibitory effect of Map4k4 expression in 
myogenic differentiation (Fig 2.10). Based on these results, we conclude that Map4k4 
regulates skeletal myogenesis at least partially by regulating Myf5 expression. 
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Figure 2.10 Myf5 expression reverses the impaired myogenic differentiation caused 
by Map4k4. C2C12 myoblasts were transfected with empty vector or a construct 
expressing Myf5. Six h later, the cells were infected with adenoviruses expressing GFP 
or Map4k4. (A) Cells were fixed and immunostained for MyHC (red) at day 3 after 
differentiation and myogenic conversion was observed by fluorescence microscopy 
(100×). (B) The fusion index was calculated for transfected cells after 3 days in DM. 
Results represent mean ± SEM from three independent experiments. *** p < 0.001. (C) 
Immunoblot of myogenic differentiation proteins. Data is representative of three 
independent experiments. 
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Discussion 
In this study we demonstrate that Map4k4 negatively regulates C2C12 myogenic 
differentiation through a Myf5-dependent mechanism. RNAi-mediated gene specific 
silencing of Map4k4 expression or expression of a Map4k4 kinase-inactive mutant 
enhances the differentiation of C2C12 myoblasts (Fig 2.2, 2.4 and 2.5), while Map4k4 
expression inhibits this process (Fig 2.5). Map4k4 suppression results in a significant 
increase in Myf5 expression at the early stage of differentiation (Fig 2.8). Furthermore, 
silencing of Myf5 inhibits C2C12 myoblast differentiation and also suppresses the ability 
of Map4k4 silencing to enhance myotube formation (Fig 2.9). In contrast, Myf5 
expression promotes myotube formation and reverses the Map4k4-mediated myogenic 
differentiation inhibition (Fig 2.10), suggesting that Map4k4 regulates C2C12 
myogenesis at least in part through Myf5.  
We found that Map4k4 does not likely mediate myogenic differentiation via activation of 
the canonical MAPK signaling pathways, although it has been reported that Map4k4 can 
act upstream of p38 MAPK, JNK and ERK. In contrast to the dramatic enhancement of 
myotube formation upon Map4k4 silencing, a slight increase of myotube formation was 
observed in ERK1-silenced cells, while suppression of other MAPKs resulted in either no 
morphological difference or smaller myotubes. In addition, no change in levels of 
phosphorylated MAPKs were observed upon Map4k4 knockdown, which further 
suggests that the Map4k4-mediated increase in myogenesis is independent of MAPKs 
(Fig 2.6). These findings implicating signaling pathways distinct from canonical MAP 
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kinase cascades are consistent with our studies of Map4k4 signaling in other cellular 
contexts. We have previously shown that Map4k4 functions to reduce lipopolysaccharide 
(LPS)-induced TNFα expression in macrophages in a MAP kinase-independent manner. 
In that study, silencing of macrophage Map4k4 had no effect on the phosphorylation of 
p38 MAPK, ERK1/2, JNK1/2 or their substrates ATF2 or c-Jun in response to LPS (7). 
Map4k4 has also been suggested to regulate lipogenesis in cultured adipocytes 
independently of JNK signaling pathway, because JNK kinase activity remained 
unaltered upon either Map4k4 silencing or overexpression as determined by anti-
phosphorylated JNK or c-Jun antibodies and protein kinase assay (Laura Danai, 
unpublished data). These findings strongly suggest that Map4k4 may regulate cellular 
processes independently of MAPK signaling pathways. The discrepancy on the 
relationship between Map4k4 and MAPKs between our studies and others’ may result 
from differences in cell types, animal models and experimental methods that have been 
used. In fact, JNK activity regulation by Map4k4 could only be observed when both 
kinases were overexpressed in 293T cells, as it has been shown in several other studies 
(254, 297), but not when the endogenous kinases were examined in these cells (Laura 
Danai, unpublished data). Of note, we have not examined whether Map4k4 may regulate 
other p38 MAPK isoforms (β, γ and δ), which have been demonstrated to be necessary 
for C2C12 myogenic differentiation (151, 277). Further investigations are required to test 
this possibility.  
In the current study, Myf5 expression was enhanced at the early stage of myogenic 
differentiation in Map4k4-depleted myocytes (Fig 2.8). We further found that Myf5 is 
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critical for myogenic differentiation because siRNA-mediated Myf5 suppression 
significantly inhibited C2C12 myoblast differentiation (Fig 2.9), consistent with the 
observations reported in a recently published study (224). Furthermore, we found that 
silencing of Myf5 reduced the enhanced myotube formation that ensued upon Map4k4 
suppression to the same level as the scrambled siRNA control (Fig 2.9), indicating that 
Map4k4 regulates myogenic differentiation in a Myf5-dependent manner. The marked 
rescue by Myf5 overexpression of myogenic differentiation inhibition because of 
Map4k4 in myoblasts demonstrates that Map4k4 regulates skeletal muscle differentiation 
by acting upstream of Myf5. Other regulators may also be involved in the regulation of 
myogenesis by Map4k4, such as proteins related to myoblast fusion that occurs in late 
differentiation. This concept is supported by the observation that Map4k4 suppression 
during late differentiation still significantly increased myotube formation (Fig 2.7, middle 
panels).  
In human skeletal muscle, Map4K4 silencing protected against TNFα-mediated insulin 
resistance by preventing activation of JNK1/2 and ERK1/2 (36). TNFα has been 
demonstrated to inhibit skeletal muscle differentiation in several studies (3, 48, 57).  
Therefore, Map4k4 may mediate in part the inhibitory effect of TNFα on C2C12 
differentiation. When C2C12 myoblasts were differentiated with DM containing 5ng/ml 
of TNFα for 3 days, we observed a marked inhibition of myotube formation, dramatically 
reduced myogenic gene MyHC expression (~10 fold) and increased phosphorylation of 
JNK1/2. However, silencing Map4k4 in TNFα-treated cells only marginally rescued the 
inhibitory effect of TNFα on C2C12 differentiation as demonstrated by a slight increase 
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in myotube formation and MyHC expression (~1.9 fold), with no significant alteration in 
JNK1/2 phosphorylation (Fig A.1). The fact that the silencing was not complete in these 
studies makes data interpretation difficult, and cells from Map4k4 knockout mice will be 
required to address whether Map4k4 plays a role in TNFα-mediated inhibition of 
myogenic differentiation.  
The negative effect of Map4k4 on myoblast fusion suggests a potential involvement of 
Map4k4 in skeletal muscle regeneration. Muscle regeneration is a rapid and extensive 
self-renewal process relying on the presence of satellite cells, a population of quiescent, 
mononucleated stem cells that are resident in adult skeletal muscle (47, 264). Upon work 
overload or injury, satellite cells are activated, then proliferate and differentiate into 
myoblasts that either fuse to each other to create new myofibers, or fuse to existing 
damaged myofibers for repair. The fusion process in regeneration shares similar features 
to muscle cell fusion in myogenic differentiation. As Map4k4 is abundantly present in 
satellite cells (Fig 2.1) and it is able to regulate myoblast fusion in C2C12 differentiation, 
it may also mediate the fusion process in muscle regeneration. Moreover, we showed 
here that Map4k4 silencing in C2C12 myoblasts substantially increased Myf5 expression 
during early myogenic differentiation (Fig 2.8). In muscle regeneration, satellite cell 
activation is associated with Myf5 up-regulation (60) and Myf5 null mice had a 
significant delay in the regenerative process (96). These studies support Map4k4 as a 
potential regulator in skeletal muscle regeneration by regulating Myf5 expression and 
fusion in satellite cells.  
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In summary, the results of this study reveal a novel role for Map4k4 in skeletal 
myogensis and identify Myf5 as a protein that is regulated by Map4k4 to mediate 
myogenic differentiation. Given the effects that Map4k4 exerts on fusion and Myf5 
expression, Map4k4 inhibition may enhance the regenerative capacity of damaged 
muscles in trauma and degenerative diseases such as muscular dystrophies. The 
hypertrophic myotube formation induced by Map4k4 suppression also suggests that 
Map4k4 may be an attractive therapeutic target for the treatment of cachexia or 
sarcopenia. Further investigation into other Map4k4 effectors that are involved in 
myogenesis, especially muscle-specific Map4k4 substrates, will be necessary to fully 
understand the role of Map4k4 as a new signaling node in muscle development and 
function.   
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Chapter III: Map4k4 does not regulate IGF-mediated 
signaling pathways in C2C12 muscle cells 
 
Contributions: All experiments and data analysis were performed by me.  
 
 
 
 
 
 
 
 
 
 
 
76 
 
76 
Abstract 
IGF signaling has profound effects on skeletal muscle size by promoting myoblast 
proliferation, differentiation and myofiber protein synthesis. siRNA-mediated silencing 
of Map4k4, a novel suppressor of myogenic differentiation, results in markedly enhanced 
myotube formation that appears identical to the hypertrophic phenotype that is caused by 
IGF signaling activation. Here we show that Map4k4 silencing does not alter IGF1-
induced effector phosphorylation including Akt, p70S6K, S6, 4EBP1 and ERK1/2 in 
C2C12 myoblasts. Map4k4 suppression neither appears to affect IGF/Akt signaling 
pathway during C2C12 myogenic differentiation, as demonstrated by unchanged 
phosphorylation of Akt and its substrates GSK3 and FoxO1 as well as mTOR substrates 
p70S6K and 4EBP1. Furthermore, no change in the expression of FoxO1 targets MAFbx 
and MURF1 was observed in Map4k4-silenced C2C12 cells during differentiation. These 
results demonstrate that Map4k4 is not involved in IGF signaling-mediated skeletal 
muscle differentiation and hypertrophy.       
Introduction 
Skeletal muscle is a dynamic tissue that can alter its size as an adaption to various 
environmental stimuli such as nutrients, hormones and exercise. Increased muscle mass 
(i.e. muscle hypertrophy) is characterized by elevated myonuclei number and myofiber 
protein content, which are mediated by molecular signaling pathways that are involved in 
myoblast proliferation, differentiation and protein metabolism. Insulin-like growth factor 
(IGF) is a potent modulator of skeletal muscle mass. Forced IGF1 expression in mouse 
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skeletal muscle resulted in increased myoblast proliferation, protein synthesis and 
significant myofiber hypertrophy (15, 56, 88, 188), while IGF1 or IGF1 receptor deletion 
caused dramatic muscle hypoplasia and severe growth retardation (14, 158, 219). An 
array of studies in multiple muscle cell lines also identified IGF1 and IGF2 as important 
inducers of myoblast proliferation and differentiation in vitro (84, 89, 251, 268). 
Signaling through the IGF receptor stimulates several different downstream intracellular 
signaling cascades including ERK1/2 and Akt signaling. IGF induced-ERK activation is 
mainly responsible for mitogenesis (59, 178), although the IGF/Akt axis is critical for 
proliferation as well (178, 273). Akt activation promotes myogenic differentiation and 
hypertrophy by targeting three major downstream kinases: mTOR, GSK3β and FoxO. 
Akt-mediated mTOR activation stimulates protein synthesis via p70S6K1 activation and 
4EBP1 inhibition. P70S6K1 phosphorylates the small ribosomal subunit S6 to initiate 
efficient mRNA translation and phosphorylated 4EBP1 releases its inhibitory binding to 
eIF4E, further allowing for the translation initiation. GSK3β phosphorylation by Akt 
inactivates this kinase, therefore abolishing the inhibitory effects of GSK3β on muscle 
differentiation and protein synthesis. Similarly, Akt-mediated phosphorylation of FoxO, a 
negative regulator of myogenesis, prevents its nuclear translocation, resulting in 
enhanced muscle differentiation and down-regulation of two atrophy-inducing, muscle-
specific ubiquitin ligases MAFbx and MuRF1, which are FoxO1 transcription targets 
(171).   
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Map4k4 is a serine/threonine protein kinase that belongs to the germinal center kinase 
GCK-IV group of Saccharomyces cerevisiae sterile 20 protein kinases (74). In an RNAi-
based screen for regulators of adipocyte function, Map4k4 was discovered to inhibit 
PPARγ expression in cultured adipocytes (263). A following study suggested that the 
PPARγ suppression by Map4k4 was at the translational level involving mTOR signaling 
(102). Map4k4 silencing activated mTOR, and increased phosphorylation of its substrate 
4EBP1 but not p70S6K. 4EBP1 phosphorylation releases its inhibitory binding to eIF4E 
and allows 5’-cap-dependent translation initiation, resulting in increased PPARγ protein 
levels and global protein synthesis rates in Map4k4-silenced adipocytes (102).  
We have recently identified Map4k4 as a novel suppressor of skeletal muscle 
differentiation (278). Map4k4 suppression by RNAi technology or kinase-inactive 
Map4k4 overexpression in C2C12 myoblasts dramatically enhanced myotubes formation 
with increased myonulcei number and myotube size (Fig 2.2 and 2.5, (278)), which 
phenocopied IGF1 or IGF2-induced myotube hypertrophy (251, 268). The Map4k4 
silencing-stimulated myotube formation was partially because of elevated Myf5 
expression, which was required for the enhancement of myotube formation in Map4k4-
silenced cells and was sufficient to rescue Map4k4-mediated inhibition of myogenic 
differentiation (Fig 2.8, 2.9 and 2.10, (278)). However, other mechanisms may contribute 
to Map4k4-mediated suppression of muscle differentiation because Myf5 silencing only 
partially impaired the Map4k4 depletion-induced myotube formation.  
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We hypothesized that Map4k4 might regulate muscle differentiation and hypertrophy 
through an IGF-mediated signaling pathway because of the high similarity between the 
muscle phenotypes caused by Map4k4 silencing and IGF induction. We were particularly 
interested in a potential role for Map4k4 in mTOR regulation because it is a downstream 
effector of IGF-Akt signaling in muscle cells and because Map4k4 suppressed the 
mTOR/4EBP1 signaling cascade in cultured adipocytes (102).    
Materials and Methods 
Cell culture and transfection. Mouse C2C12 myoblasts (American Type Culture 
Collection) were cultured in growth media (GM) consisting of Dulbecco’s modified 
Eagle’s media (DMEM) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin at 37°C with 5% CO2. To induce differentiation, 95% confluent 
cells were placed in differentiation media (DM) consisting of DMEM with 2% horse 
serum. For siRNA transfection, C2C12 myoblasts cultured in growth media were 
transfected with 50 pmol siRNA using Lipofectatmine RNAiMAX (Invitrogen) 
according to the manufacturer’s instructions for reverse transfection. Twenty-four hours 
later, cells were switched to DM and cultured for the indicated times before harvesting.  
Western blotting. Cells were solubilized with ice-cold lysis buffer (20 mM HEPES, pH 
7.2, 100 mM NaCl, 1mM EDTA, 100 mM PMSF, 0.01% Triton X-100, 1% SDS and 
Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific)), and protein 
concentrations were assessed by BCA assay (Thermo Scientific). Equal amounts of 
protein were loaded onto 8.5% SDS-polyacrylamide gels and transferred to nitrocellulose 
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membranes. The following antibodies were used: anti-Map4k4 (Bethyl), anti-phospho-
p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (Cell Signaling), anti-p44/42 MAPK (ERK1/2) 
(Santa Cruz), anti-phospho-Akt (Ser473) (Cell Signaling), anti-Akt (Cell Signaling), anti-
phospho-GSK3α/β (Ser21/9) (Cell Signaling), anti-GSK3α/β (Cell Signaling), anti-
phospho-FoxO1 (Ser256) (Cell Signaling), anti-FoxO1 (Cell Signaling), anti-phospho-
p70S6K (Thr389) (Cell Signaling), anti-p70S6K (Cell Signaling), anti-phospho-S6 
ribosomal protein (Ser240/244) (Cell Signaling), anti-S6 ribosomal protein (Cell 
Signaling), anti-phospho-4EBP1 (Thr37/46) (Cell Signaling) and anti-4EBP1 (Cell 
Signaling) antibodies. 
Isolation of RNA and Real Time PCR. RNA isolation was performed according to the 
Trizol Reagent Protocol (Invitrogen). cDNA was synthesized from 1.5 μg total RNA 
using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules CA) according to the 
manufacturer’s instructions. For real time PCR, synthesized cDNA and iQ SYBR Green 
Supermix were run on the MyiQ Real-Time PCR System (Bio-Rad) with following 
primer pairs: MAFbx forward 5’-ATGCACACTGGTGCAGAGAG-3’, MAFbx reverse 
5’-TGTAAGCACACACTGCAGGTC-3’; MuRF1 forward 5’-
ACGAGAAGAAGACTCGAGC-3’, MuRF1 reverse 5’-CTTGGCACTTGAGAGGAA-
3’. 36B4 was used as an internal loading control. Relative gene expression was 
determined using the ΔCt method. 
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Results 
Map4k4 silencing does not alter IGF1-induced ERK1/2 phosphorylation in C2C12 
myoblasts.  
IGF1 promotes myoblast proliferation by activating the ERK1/2 signaling pathway (59, 
178). To investigate whether Map4k4 regulates the IGF1-ERK1/2 signaling axis, we 
suppressed Map4k4 expression using siRNA in C2C12 myoblasts and examined IGF1-
induced ERK1/2 phosphorylation at multiple time points. IGF1 transiently activated 
ERK1/2 as indicated by the increased ERK1/2 phosphorylation at Ser202/204 within 15 
minutes of IGF1 treatment (Fig 3.1). However, no significant alteration in ERK1/2 
phosphorylation was observed in Map4k4-silenced myoblasts compared with the 
scrambled siRNA controls (Fig 3.1), suggesting that Map4k4 is not involved in IGF1-
induced ERK1/2 activation.  
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Figure 3.1 Map4k4 silencing does not alter IGF1-induced ERK1/2 phosphorylation 
in C2C12 myoblasts. C2C12 myoblasts were transfected with scrambled siRNA or 
siRNA against Map4k4. 24 h later, the cells were starved for 2 h and then treated with 
IGF1 (100ng/ml) for the indicated times. ERK1/2 phosphorylation was assessed by 
Western blotting using the indicated antibodies. A representative Western blot is shown. 
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Map4k4 silencing does not affect IGF1/Akt/mTOR signaling in C2C12 myoblasts.  
In addition to ERK1/2, IGF1 also activates Akt signaling in myoblasts. Downstream of 
Akt, several signaling branches are activated by IGF including the mTOR signaling 
pathway. Because Map4k4 selectively inhibited mTOR activity and 4EBP1 
phosphorylation in adipocytes, we aimed to determine whether Map4k4 modulates 
IGF1/Akt/mTOR signaling in muscle cells. To test this, we used Map4k4 siRNA to 
deplete its expression in C2C12 myoblasts and monitored the phosphorylation of 
downstream IGF1/Akt/mTOR signaling pathway effectors at multiple time points after 
IGF1 treatment. In the scrambled siRNA control cells, IGF1 activated Akt as early as 5 
minutes after stimulation, and this activation lasted for at least 90 minutes (Fig 3.2). 
mTOR substrate p70S6K phosphorylation was induced 5 minutes after IGF1 treatment 
and began to decrease after 60 minutes, which was similar to the p70S6K substrate S6 
ribosomal protein, which peaked at 30 minutes in IGF1-treated cells (Fig 3.2). 4EBP1 
phosphorylation was stimulated at 5 minutes, peaked at 30 minutes and began to decrease 
slightly after that (Fig 3.2). The time-dependent and sequential phosphorylation of Akt 
and downstream mTOR effectors indicated that IGF1 sufficiently activated Akt/mTOR 
signaling in C2C12 myoblasts and the time window that we chose was appropriate to 
study the role of Map4k4 in the signaling cascade. Upon Map4k4 depletion, the 
phosphorylation status of each effector remained similar compared with the scrambled 
control, implying that Map4k4 does not regulate the IGF/Akt/mTOR signaling pathway 
in C2C12 myoblasts.           
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Figure 3.2 Map4k4 silencing has no significant effect on the IGF/Akt/mTOR 
signaling pathway in C2C12 myoblasts. C2C12 myoblasts were transfected with 
scrambled or Map4k4 siRNA. 24 h later, the cells were starved for 2 h and then treated 
with IGF1 (100ng/ml) for the indicated times. IGF/Akt/mTOR signaling pathway 
activation was assayed by Western blotting using the indicated antibodies.  The data is 
representative of four independent experiments. 
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Map4k4 silencing has no impact on Akt or its downstream effector activation during 
C2C12 differentiation.  
Myoblasts begin to express IGF2 upon serum withdrawal and continuously produce IGF2 
with muscle differentiation in vitro (89). Several studies have demonstrated that 
myogenic differentiation is mediated through endogenous Akt activation that is induced 
by autocrine/paracrine IGF2 (89, 183). To assess whether Map4k4 regulates myogenesis 
through endogenous Akt signaling, C2C12 myoblasts were transfected with scrambled or 
Map4k4-targeting siRNA and Akt signaling pathway component phosphorylation was 
examined by Western blotting at multiple time points during muscle differentiation. Akt 
signaling was relatively active in the myoblasts, as demonstrated by the high Akt 
phosphorylation levels as were the downstream effectors including GSK3, FoxO1 and 
mTOR substrates p70S6K and 4EBP1 (Fig 3.3A). Serum withdrawal, a crucial step to 
induce myogenic differentiation, dramatically inactivated Akt signaling, which was 
rebounded gradually with C2C12 differentiation (Fig 3.3A). Map4k4 silencing did not 
result in any significant changes in the phosphorylation of Akt or its downstream 
effectors (Fig 3.3A). The expression of MAFbx and MURF1, two targets of the 
transcription factor FoxO1 were not altered in the Map4k4-silenced muscle cells 
compared with scrambled siRNA-treated controls (Fig 3.3B), suggesting that FoxO1 
transcriptional activity did not change upon Map4k4 suppression. These findings indicate 
that Map4k4 does not modulate myogenic differentiation through the endogenous Akt 
signaling pathway.          
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Figure 3.3 Map4k4 silencing has no impact on activation of Akt or its downstream 
effectors during C2C12 differentiation. C2C12 myoblasts were transfected with 
scrambled or Map4k4 siRNA. 24 h later, the cells were transferred to DM for the 
indicated times. (A) Activation of Akt signaling during muscle differentiation was 
determined by immunoblotting with the indicated antibodies. The data is representative 
of at least three independent experiments. (B) MAFbx and MuRF1 expression was 
assessed by real-time RT-PCR. The data represent the mean ± SEM from three 
independent experiments. 
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Discussion 
In a previous study, we identified Map4k4 as a novel suppressor of skeletal muscle 
differentiation (Chapter 2 and (278)). Map4k4 silencing in C2C12 myoblasts resulted in a 
dramatic enhancement of myotube formation that is reminiscent to the hypertrophic 
myotubes caused by IGF, which is a potent inducer of myoblast proliferation, myogenic 
differentiation and muscle hypertrophy both in vitro and in vivo. In the current study, we 
discovered that Map4k4 appeared not to be involved in two IGF signaling branches, the 
IGF/ERK1/2 signaling axis and the IGF/Akt signaling axis. No significant alterations in 
IGF-induced phosphorylation of ERK1/2, Akt or its downstream effectors were detected 
in Map4k4-silenced cells compared with the scrambled controls (Fig 3.1 and 3.2). 
Endogenous Akt signaling activity was also unchanged during myogenic differentiation 
in Map4k4-depleted muscle cells (Fig 3.3).   
Previous studies have demonstrated that IGF induces myoblast proliferation through 
activating both ERK1/2 and Akt signaling pathways. The failure to detect ERK1/2 and 
Akt phosphorylation upon Map4k4 suppression (Fig 3.1 and Fig 3.2) is consistent with 
unchanged EdU incorporation into kinase-inactive Map4k4-overexpressing C2C12 cells 
as demonstrated in Fig 2.3, further suggesting that Map4k4 does not play a role in 
myoblast proliferation.   
mTOR signaling is a key signaling branch downstream of Akt. Map4k4 silencing in 
cultured adipocytes promoted PPARγ translation and global protein synthesis via mTOR 
signaling pathway activation. However, Map4k4 silencing in C2C12 myoblasts had no 
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detectable effects on the mTOR signaling pathway during myogenic differentiation, as 
determined by unaltered phosphorylation of mTOR downstream effectors p70S6K and 
4EBP1 (Fig 3.2). Moreover, Map4k4 suppression did not enhance IGF/Akt/mTOR 
signaling in the IGF1-treated C2C12 myoblasts compared with the scrambled siRNA 
controls (Fig 3.3). These results indicate that Map4k4 may not target the canonical 
mTOR signaling pathway during skeletal muscle differentiation. Notably, the myogenic 
function of mTOR during early differentiation has been demonstrated to be kinase-
independent and involves neither of the downstream effectors p70S6K1 or 4EBP1 (85). 
Instead, mTOR induces IGF2 transcription in a kinase-independent mechanism and thus 
activates Akt signaling indirectly (86). We have preliminary data showing that Map4k4 
silencing resulted in a trend to increased IGF2 mRNA expression during C2C12 
differentiation, implying that Map4k4 may target mTOR without altering its kinase 
activity to regulate IGF2 expression and thereby myogenesis. However, this hypothesis 
contradicts with the lack of alteration in IGF/Akt signaling upon Map4k4 silencing 
during C2C12 differentiation (Fig 3.3). One possibility is that the observed IGF2 up-
regulation is only at the transcriptional level. Further investigation will be required to 
determine whether IGF2 protein content is altered in the Map4k4-silenced muscle cells.           
GSK3β phosphorylates and inactivates the eukaryotic initiation factor eIF2B, a guanine 
nucleotide exchange factor that converts the inactive GDP-bound eukaryotic initiation 
factor 2 (eIF2) to the active GTP-bound eIF2, therefore impairing mRNA translation and 
global protein synthesis (282). Insulin stimulation induces dephosphorylation of the 
eIF2B inhibitory site by phosphorylating and inactivating GSK3β at Ser9 in a PI3K-
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dependent manner, indicating that insulin (or IGF) stimulates translation through 
PI3K/Akt/GSK3β/eIF2B/eIF2 signaling independently of mTOR (282). In the present 
study, we did not detect any changes in GSK3β phosphorylation upon Map4k4 silencing 
in C2C12 muscle cells, implying that Map4k4 would not regulate protein synthesis via 
the IGF/Akt/GSK/eIF2B/eIF2 pathway. A similar result was obtained in Map4k4-
deficient mouse embryonic fibroblasts; in these cells, GSK3α/β phosphorylation 
remained unchanged from wild-type controls (Laura Danai, unpublished data). However, 
evidence from co-immunoprecipitation experiments suggested a potential interaction 
between Map4k4 and one of the eIF2 regulators in cultured adipocytes (Adilson 
Guilherme, unpublished data), therefore Map4k4 may modulate the regulator activity by 
phosphorylation and thus affecting eIF2 activity in a GSK3β-independent manner. 
Map4k4 silencing-induced muscle hypertrophic phenotype may result from eIF2 
activation-induced increases in protein accumulation. To test this hypothesis, we would 
need to determine whether Map4k4 regulates global protein synthesis in skeletal muscle. 
Further investigations are required to confirm the interaction between Map4k4 and the 
eIF2 regulator in muscle cells and determine the functional effects of the interaction. 
In the present study, we have provided evidence that Map4k4 does not regulate muscle 
differentiation by interfering with the IGF-induced ERK1/2 or Akt signaling pathways. 
However, the calcineurin/NFAT signaling pathway is also downstream of the IGF 
receptor has not been assessed. Numerous studies have revealed the positive roles of 
calcineurin and its target NFATs in skeletal muscle differentiation and hypertrophy (73, 
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79, 94, 180). An interesting future study is to determine whether Map4k4 targets the 
calcineurin signaling to regulate skeletal myogenesis.   
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CHAPTER IV:  Discussion 
We have identified Map4k4 as a novel suppressor of skeletal myogenesis. Map4k4-
mediated differentiation inhibition is not through the MAP kinase signaling pathways or 
the IGF-activated Akt signaling cascades. Instead, Map4k4 regulates Myf5 expression, 
which is the first MRF that is expressed during skeletal muscle development and marks 
the commitment of the muscle lineage. When Map4k4 was silenced in C2C12 myoblasts, 
the enhanced myotube formation was correlated with a transient increase in Myf5 
expression at the early stage of differentiation (Fig 2.2 and 2.8).  
Map4k4 and MAPKs 
Role of Myf5 in skeletal muscle differentiation 
It is unclear whether Myf5 up-regulation is a primary cause of the promoted myogenic 
differentiation because data from different studies are controversial. Early studies 
demonstrated that Myf5 induced myogenic conversion of non-muscle cells (9, 11, 39). 
Ectopic Myf5 expression in embryonic C3H10T1/2 fibroblasts resulted in multinucleated 
syncytia formation and muscle-specific gene expression (39) as well as a rapid and 
sustained increase in endogenous myogenin mRNA (108). In contrast, an antisense Myf5 
oligomer abolished IGF2-induced myogenin transcription, creatine kinase elevation and 
cell fusion in L6 muscle cells (170). Defective myotube formation was also observed in 
C2C12 myoblasts that were targeted with Myf5 antisense oligonucleotides or shRNA (71, 
224). These data suggest that Myf5 is necessary and sufficient for myogenic 
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differentiation. However, evidence from Myf5-null primary myoblasts implied an 
inhibitory role of Myf5 on myogenesis (184). These cells underwent precocious 
differentiation with attenuated proliferative ability, indicating that Myf5 was favorable 
for proliferation. In addition, Myf5 overexpression in C2C12 cells failed to increase the 
myotube fusion index, although higher expression of muscle genes including myogenin 
and MCK was observed in the transfected cells (31).  
In our study, Myf5 was a positive mediator of C2C12 differentiation. Myf5 silencing 
impaired myotube formation with a decreased fusion index and decreased muscle gene 
expression (Fig 2.9) while forced Myf5 expression significantly promoted myogenesis 
(Fig 2.10). In vivo studies have indicated a redundant relationship between Myf5 and 
MyoD (41, 97, 105, 236), and we detected an increase in MyoD protein level upon Myf5 
silencing during C2C12 differentiation (Fig 2.9C). However, up-regulated MyoD seemed 
to fail to completely compensate for the Myf5 loss in our study, because impaired 
myotube formation was still observed upon Myf5 silencing in C2C12 cells (Fig 2.9A), 
indicating that Myf5 plays an independent role in myogenic differentiation at least in 
vitro. We did not detect any significant change in MyoD expression in Map4k4-silenced 
C2C12 cells (Fig 2.4 and Fig 2.9C), but a preliminary experiment in mouse primary 
satellite cells showed that both Myf5 and MyoD expression increased upon Map4k4 
silencing during muscle differentiation, associating with enhanced myotube formation 
observed in the Map4k4-silenced cells (Mengxi Wang, unpublished data). This finding 
indicates that both Myf5 and MyoD could be the downstream effectors of Map4k4 to 
regulate myogenic differentiation in primary muscle cells. In addition, although MyoD 
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expression was unaltered upon Map4k4 suppression, its transcriptional activity may 
increase to promote myogenic differentiation. Further investigations are required to 
examine Myf5 and MyoD transcriptional activities upon Map4k4 suppression or ectopic 
expression, especially in primary satellite cells.            
Regulation of Myf5 expression by Map4k4 in C2C12 muscle cells 
A transient increase in Myf5 expression was detected upon Map4k4 silencing in C2C12 
muscle cells (Fig 2.8), suggesting that Map4k4 is a negative regulator of Myf5 expression 
during early myogenic differentiation. It is also supported by a correlation between the 
increased Myf5 expression (Fig 2.8) and reduced Map4k4 protein level as well as kinase 
activity (Fig 2.1, B and C) at earlier time points during muscle differentiation in the 
controlled cells. It is unclear why Map4k4 expression and kinase activity are decreased 
during C2C12 myogenic differentiation. Serum withdrawal might be one trigger for the 
expression down-regulation, because Map4k4 has been suggested to be a serum-response 
factor (SRF)-regulated gene in cardiac cell differentiation (303). Growth factors, 
cytokines and hormones that are abundant in fetal bovine serum are potential regulators 
of Map4k4 kinase activity, and further research is needed to find out mechanisms by 
which Map4k4 is regulated during skeletal myogenesis.   
We performed double knockdown experiments and observed that Map4k4 silencing-
induced myogenic differentiation was attenuated by Myf5 suppression (Fig 2.9), whereas 
the defective myogenesis caused by ectopic Map4k4 expression was rescued by Myf5 
activation (Fig 2.10), supporting the involvement of Myf5 in Map4k4-mediated muscle 
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differentiation. Notably, RNAi-mediated Myf5 suppression failed to completely abolish 
Map4k4 silencing-promoted muscle differentiation because the myotubes with the double 
knockdown were bigger than the one resulted from Myf5 silencing only (Fig 2.9A). On 
one hand, other downstream effectors beside Myf5 are probably also involved in Map4k4 
regulation of myogenic differentiation. On the other hand, Myf5 might not be suppressed 
as efficiently at the double knockdown condition as it was silenced alone. Satellite cells 
with complete deletion of Map4k4 and Myf5 will be better tools than C2C12 muscle cell 
line with siRNA-mediated gene suppression to determine the regulatory relationship 
between Map4k4 and Myf5 as well as their roles in muscle differentiation.  
Myf5 expression was affected by Map4k4 at both the mRNA and protein levels. The 
mechanisms by which Map4k4 modulates Myf5 activation are important directions for 
future research. There are several hypotheses that we are testing or have tested to provide 
more information on the mechanistic aspects of the relationships among Map4k4, Myf5 
and myogenesis.      
Pax3 activates Myf5 transcription during skeletal muscle development (13, 242). We 
measured Pax3 expression during C2C12 differentiation in the Map4k4-silenced cells and 
scrambled controls. Pax3 mRNA levels were relatively low in the control myoblasts as 
suggested by high Ct numbers obtained from real-time RT-PCR and decreased further 
with myogenic differentiation. Map4k4 silencing did not significantly change Pax3 
expression during myogenesis, indicating that Pax3 is probably not the cause of Map4k4 
suppression-induced Myf5 transcription at the early stage of differentiation (Fig A.2). It 
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is still possible that Map4k4 regulates Pax3 transcriptional activity to affect Myf5 
expression. Experiments such as luciferase assays would be needed to test this hypothesis.  
Myf5 is also a direct target of canonical Wnt signaling, in which activated β-catenin 
binds to Tcf/Lef sequences in the regulatory region of Myf5 promoter to induce Myf5 
expression in vivo and in vitro (29, 107, 122). A recent study discovered that R-spondin2 
(RSPO2), a Wnt/β-catenin signaling activator, induced Myf5 expression and myogenic 
differentiation via the canonical Wnt pathway in C2C12 muscle cells (107). RSPO2-
stimulated Myf5 up-regulation was impaired by treating the cells with DKK1, an 
antagonist for Wnt/β-catenin signaling that acts on LRP5/6 receptors (244). These 
findings implied a possible involvement of canonical Wnt signaling in Map4k4-mediated 
Myf5 transcription and myogenic differentiation. In fact, we detected an increase in the 
expression of RSPO family gene RSPO3 during the early stages of C2C12 differentiation 
upon Map4k4 silencing (Fig A.3A). Myoblasts treated with RSPO3 had enhanced Myf5 
mRNA and protein expression (Fig A.3, C and D), and differentiated into bigger 
myotubes with higher MyHC expression (Fig A.3B). These data indicated a potential for 
Map4k4/RSPO3/β-catenin signaling that regulates Myf5 transcription. However, Map4k4 
silencing in myoblasts failed to induce a further increase in Myf5 mRNA level upon 
RSPO3 treatment and vice versa (Fig A.2E), suggesting that Map4k4 does not regulate 
Myf5 transcription by targeting RSPO3. In addition, Map4k4 depletion did not activate a 
classic Wnt/β-catenin signaling target gene Axin2 expression in C2C12 myoblasts, while 
exogenous RSPO3 or another canonical Wnt signaling activator Wnt3a did (Fig A3.E), 
implying that Map4k4 may not regulate β-catenin activity. Consistently, no significant 
97 
 
97 
changes of β-catenin nuclear accumulation were observed upon Map4k4 silencing in the 
basal, Wnt3a- or RSPO3- treated conditions (Fig A3.F). Based on these results, we 
believe that Map4k4-mediated Myf5 expression is Wnt/β-catenin signaling-independent. 
Although the RSPO3 transcripts were increased by Map4k4 silencing, RSPO3 protein 
levels were not measured. It is possible that RSPO3 protein levels remain unchanged in 
response to Map4k4 depletion, and other unknown effectors that negatively regulate 
Wnt/β-catenin signaling could be activated upon Map4k4 suppression, thus masking the 
promoting role of RSPO3 in the signaling pathway.  
A calcineurin/NFAT-dependent pathway can regulate Myf5 expression in skeletal muscle 
reserve cells, a group of non-dividing satellite cell-like cells in myotube cultures. The 
calcium-activated phosphatase calcineurin dephosphorylates NFAT, resulting in the 
nuclear translocation of NFAT to activate Myf5 transcription in reserve cells (95). In 
addition to controlling Myf5 expression in reserve cells, calcineurin and its target NFATs 
have been implicated to positively regulate skeletal muscle differentiation and 
hypertrophy (73, 79, 94). Different NFAT family genes are expressed at distinct stages of 
myogenic differentiation and regulate various aspects of myogenesis (1) with NFATc3 
expressed mainly in myoblasts promoting nascent myotube formation (180), while 
NFATc1 and NFATc2 are mainly found in myocytes and myotubes and are involved in 
myoblast-myotube fusion and muscle hypertrophy (117-118, 189, 245). We have 
preliminary data revealing a faster gel migration pattern of NFATc3 protein from C2C12 
myoblast cytosolic and nuclear extracts upon Map4k4 silencing, suggesting that Map4k4 
may mediate NFATc3 phosphorylation and thus nuclear translocation in myoblasts (Fig 
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A.4). However, this effect of Map4k4 silencing on NFATc3 phosphorylation and nuclear 
translocation may not be sufficient to explain the enhanced Myf5 transcriptional 
activation upon Map4k4 silencing, because NFAT has been shown to regulate Myf5 
expression only in reserve cells, but not in proliferating myoblast cultures (95). The 
regulatory interaction between Map4k4 and NFATc3 shed light on another potential 
mechanism by which Map4k4 regulates skeletal muscle differentiation. More 
experiments are required to confirm the effect of Map4k4 in NFATc3 phosphorylation 
and determine its functional outcome in myogenesis. It would also be interesting to 
determine whether the decreased NFATc3 phosphorylation observed upon Map4k4 
depletion is mediated through direct interactions between Map4k4 and NFATc3 or by 
regulating NFATc3 upstream modulators including the phosphatase calcineurin or 
kinases such as GSK3β, which phosphorylates and inactivates NFATc3 in C2C12 muscle 
cells (272). In addition, the relationship between Map4k4 and other NFAT genes (eg. 
NFATc1 and NFATc2) could be examined to determine whether Map4k4 regulates 
myoblast fusion and muscle hypertrophy in an NFAT-dependent manner. 
We have observed a modest increase in Myf5 mRNA (~1.4 fold) but an abundant 
increase (~3 fold) in Myf5 protein in Map4k4-silenced myocytes. The discrepancy 
between Myf5 mRNA and protein levels suggests the possibility that Map4k4 may 
regulate Myf5 at the translational or post-translational level. Map4k4 silencing in 
cultured adipocytes promoted PPARγ translation and global protein synthesis through 
activating mTOR/4EBP1 signaling pathway (102), thus Map4k4 may regulate Myf5 in 
the same manner. We did detect a marked increase in Myf5 protein levels in Map4k4-
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silenced C2C12 cells by western blotting (Fig 2.8). However, Map4k4 silencing in 
C2C12 myoblasts had no detectable effect on the mTOR signaling pathway during 
myogenic differentiation as determined by unaltered phosphorylation of downstream 
effectors mTOR p70S6K and 4EBP1 (Fig 3.3). Moreover, Map4k4 suppression did not 
enhance IGF/Akt/mTOR signaling in IGF1-treated C2C12 myoblasts compared with 
scrambled siRNA controls (Fig 3.2). These results suggest that Map4k4 may not be a 
regulator of the mTOR signaling pathway in skeletal muscle. It is still possible that 
Map4k4 mediates Myf5 translation through other mechanisms such as regulating 
translation initiation factor eIF2 activity, because a potential interaction between Map4k4 
and one of the eIF2 regulators has been detected in cultured adipocytes (Adilson 
Guilherme, unpublished data). Further investigations are required to determine whether 
Map4k4 interacts with the eIF2 regulator in C2C12 myocytes, and global protein 
synthesis could be examined upon Map4k4 silencing. More importantly, [35S] methionine 
incorporation studies that specifically measure radioactive amino acid incorporation into 
Myf5 protein should be conducted to ensure that the Myf5 protein level alteration is 
caused by Map4k4-mediated Myf5 translation, but not only due to the different amounts 
of Myf5 transcripts available for protein synthesis. Besides enhanced translation, the 
increased Myf5 protein content could also be because of reduced protein degradation. 
However, I could not detect a difference in Myf5 protein stability in Map4k4-silenced 
myoblasts compared with scrambled controls (Fig A.5).  
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Potential role of Map4k4 in skeletal muscle development and regeneration 
To further understand the role of Map4k4 in skeletal muscle development, we are 
deleting Map4k4 using the Cre/loxP recombination system in mice. Distinct Cre mouse 
strains including Myf5-Cre and Myogenin-Cre mice will be used to delete Map4k4 in 
committed myoblasts and differentiating myocytes respectively during myogenesis. 
Because Map4k4 suppression in C2C12 myoblasts resulted in hypertrophic myotube 
formation (Fig 2.2), skeletal muscle mass is expected to be greater in Map4k4 
flox/flox:Myf5-Cre mice compared with flox/flox controls. Map4k4 flox/flox:Myogenin-
Cre mice would display increased myofiber diameter because of enhanced fusion ability 
upon Map4k4 silencing as demonstrated in cultured muscle cells (Fig 2.7). 
The effects that Map4k4 exerts on fusion and Myf5 expression in vitro also suggest a 
potential role for Map4k4 in skeletal muscle regeneration, which is a rapid and extensive 
self-renewal process that relies on satellite cells. These cells are maintained quiescent in 
basal conditions and become activated in response to muscle damage or contraction. 
Activated satellite cells proliferate, migrate to the injury site and differentiate into 
myoblasts that fuse to restore skeletal muscle architecture. To determine the role of 
Map4k4 in skeletal muscle regeneration, Map4k4 flox/flox mice will be crossed with 
Pax7-CreERT2 mice, whose Cre recombinase expression will be induced by tamoxifen in 
Pax7-positive cells that represent satellite cells (187). Tamoxifen will be delivered by 
gavage to delete Map4k4 in satellite cells in adult Map4k4 flox/flox:Pax7-CreERT2 mice, 
and cadiotoxin will be injected into the right tibialis anterior (TA) muscle of these mice 
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to induce regeneration while uninjected left TA muscle will be used as the control. Myf5 
up-regulation is associated with satellite cell activation (60)  and Myf5 null mice display 
compromised regenerative myogenesis (96, 269), suggesting that Myf5 is a positive 
regulator of skeletal muscle regeneration. Because Map4k4 silencing enhanced myoblast 
fusion and Myf5 expression in C2C12 muscle cells, Map4k4 flox/flox:Pax7-CreERT2 mice 
with tamoxifen treatment would be expected to have improved skeletal muscle 
regenerative capacity compared with controls. However, satellite cell migration is an 
important step during muscle regeneration, and Map4k4 has been demonstrated to 
positively regulate tumor cell motility (58) and stimulate presomitic mesodermal cell 
migration in a nonautonomous manner during embryogenesis (293). Therefore, deleting 
Map4k4 in satellite cells may interfere with their proper migration to the injury site, 
resulting in impaired skeletal muscle regeneration. In addition, Map4k4 silencing was 
suggested to reduce cell proliferation in hepatocyte carcinoma cell lines (157). Although 
no effect of Map4k4 on proliferation was observed in C2C12 myoblasts (Fig 2.3), it is 
still possible that Pax7-Cre-mediated Map4k4 deletion during early regeneration would 
induce precocious differentiation of satellite cells, leading to depletion of the progenitor 
cell pool and increased formation of new muscle fibers (hyperplasia).   
Mdx mouse model is another tool to study the role of Map4k4 in skeletal muscle 
regeneration. Mdx mice lack the X-linked dystrophin gene that encodes a cytoskeletal 
protein involved in plasma membrane stabilization and signaling transduction between 
extracellular matrix and intracellular cytoskeleton (67). These mice display a persistent 
and progressive cycle of degeneration and regeneration in skeletal limb muscles and 
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represent a mouse model for human Duchenne muscular dystrophy (DMD) (67). To 
study the function of Map4k4 in regenerative myogenesis, skeletal muscle specific 
Map4k4-deficient mdx mice will be generated by crossing mdx mice with Map4k4 
flox/flox:Myf5-Cre mice, which have Map4k4 deletion in embryonic myoblasts and 
approximately 90% of satellite cells that are Myf5-postive (144). Parameters including 
skeletal muscle morphology, muscle fiber membrane integrity, fibrosis, immune cell 
infiltration, muscle strength and satellite cell proliferation and differentiation will be 
compared between the Map4k4 flox/flox:Myf5-Cre/mdx mice and the mdx controls. It is 
difficult to predict the phenotype of skeletal muscle specific Map4k4-deficient mdx mice 
considering the undetermined effects of Map4k4 on satellite cell migration and 
proliferation. I would expect to observe improved skeletal muscle regeneration and 
muscular dystrophy in the Map4k4 flox/flox:Myf5-Cre/mdx mice if Map4k4 deletion has 
no inhibitory effect on satellite cell migratory and replicative capacities.   
Conclusion 
This thesis provides evidence for a novel inhibitory function of Map4k4 in skeletal 
muscle differentiation. The repression is modulated in a Myf5-dependent manner, 
independently of Akt signaling or MAP kinases that have been identified to act 
downstream of Map4k4. Other regulators may be also involved in the Map4k4-mediated 
myogenic differentiation, and NFATc3 is proposed as a candidate. The mechanisms by 
which Map4k4 regulates Myf5 expression are not clear. Pax3 and canonical Wnt 
signaling pathway, which are well studied modulators of Myf5 transcription, appear not 
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to be involved in Map4k4-mediated Myf5 expression. It will be interesting to test 
whether Map4k4 regulates Myf5 translation in muscle cells as it affects PPARγ protein 
synthesis in adipocytes in the future. In addition, I propose that Map4k4 may regulate 
skeletal muscle differentiation, fusion and regeneration in vivo, implicating Map4k4 as a 
drug target for muscle disorders such as muscular dystrophy. I believe that the work 
described herein and my future aims will shed light on Map4k4 as a new signaling node 
in muscle development and function.   
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Appendix A 
 
 
 
Fig A.1 Map4k4 silencing marginally rescued the inhibitory effect of TNFα on 
C2C12 differentiation. C2C12 myoblasts were transfected with scrambled siRNA or 
siRNA against Map4k4. 24 h later the cells were differentiated with TNFα (5ng/ml) in 
DM for 72 h. Untreated siRNA-transfected cells were used as controls. (A) Cells were 
fixed and immunostained for MyHC and myoblast differentiation was observed by 
fluorescence microscopy. (B) Immunoblot analysis of Map4k4, myogenic markers and 
JNK activation. Data is representative of three independent experiments.  
.  
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Fig A.2 Map4k4 silencing does not change Pax3 transcription. C2C12 myoblasts were 
transfected with scrambled or Map4k4 siRNA and transferred to DM for the indicated 
times 24 h post transfection. Pax3 mRNA level was determined by Real-Time PCR. Data 
is represented as the mean ± SEM of three independent experiments. 
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Fig A.3 Map4k4 silencing does not promote Myf5 transcription through activating 
RSPO3-mediated Wnt/β-catenin signaling pathway. (A) RSPO3 expression during 
myogenic differentiation. C2C12 myoblasts were transfected with scrambled or Map4k4 
siRNA and transferred to DM for the indicated times 24 h post transfection. RSPO3 
mRNA level was determined by Real-Time PCR. (B) C2C12 myoblasts were treated with 
RSPO3 (50ng/ml) for 24 h in DM and cultured in DM without RSPO3 for another 48 h. 
Cells were fixed and immunostained for MyHC and myoblast differentiation was 
observed by fluorescence microscopy (100×). MyHC expression was also assayed by 
Western blotting. (C-D) C2C12 myoblasts were treated with different amounts of RSPO3 
as indicated for 24 h in GM. Myf5 mRNA and protein levels were detected by Real-Time 
PCR and Western blotting respectively. (E-G) C2C12 myoblasts were transfected with 
scrambled or Map4k4 siRNA. 24 h later the cells were treated with RSPO3 (50ng/ml) or 
Wnt3a (25ng/ml) in GM for 24 h. Untreated siRNA-transfected cells were used as 
controls. Myf5 expression (E) or Axin2 expression (F) was examined by Real-Time PCR. 
(G) Nuclear and cytosolic factions were prepared and analyzed for Map4k4, β-catenin, 
lamin and α-tubulin protein amounts by Western blotting. Data is represented as the mean 
± SEM of three independent experiments. * p < 0.05, ** p < 0.01. 
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Fig A.4 Map4k4 silencing results in NFATc3 dephosphorylation in C2C12 myoblasts. 
C2C12 myoblasts were transfected with scrambled or Map4k4 siRNA. 48 h later 
cytosolic and nuclear protein extracts were immunoblotted with anti Map4k4, NFATc3, 
lamin and α-tubulin antibodies. Arrows on the left illustrate the change in NFATc3 
migration due to phosphorylation status. Data is representative of two independent 
experiments. 
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Fig A.5 Map4k4 silencing does not change Myf5 protein stability. C2C12 myoblasts 
were transfected with scrambled siRNA or siRNA against Map4k4. 24 h later the cells 
were treated with cycloheximide (5 µg/ml) for the indicated times. Cell lysates were 
examined by Western blot and densitometry analysis for Myf5. Densitometry is 
representative of three independent experiments. 
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